Patent Publication Number: US-2019194311-A1

Title: Methods of treating new-onset plaque type psoriasis using il-17 antagonists

Description:
RELATED APPLICATIONS 
     The instant application claims priority to U.S. Provisional Patent application No. 62/346,007, filed Jul. 19, 2016, which is incorporated by reference herein in its entirety. 
    
    
     TECHNICAL FIELD 
     The present disclosure relates to methods for treating new-onset plaque-type psoriasis patients and inhibiting psoriasis disease progression in these patients, using IL-17 antagonists, e.g., secukinumab. 
     BACKGROUND OF THE DISCLOSURE 
     Psoriasis is an immune-mediated inflammatory disease that may have a major impact on a patient&#39;s life, especially when the intensity is moderate or severe. Treatment of psoriasis during the first years is typically conservative and frequently based on topical agents which rarely clear lesions completely. Treatment with systemic agents, including biologicals, is often initiated only when topical agents, phototherapy and conventional systemic treatment have proved to be inadequate, even in patients with moderate to severe disease. (Maza et al (2012) Br J Dermatol; 167(3):643-8.). 
     Psoriatic skin lesions are a “riot” of disorder, featuring dense inflammatory cell infiltrates, massive proliferation, impaired differentiation of the epidermis, formation of new blood vessels, and alterations in lymphatic structures. With effective therapy of chronic psoriasis, there is resolution of epidermal thickness, reduced numbers of inflammatory cells, and return of previously affected skin to a clinically normal state. Once therapy is discontinued, however, psoriatic skin lesions tend to recur, usually at the same sites that were previously affected, but sometimes also appearing at new sites. 
     Therefore, there is a need for a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway (early intervention) with the goal of complete clearance, which may improve control of cutaneous symptoms and modify the course of the disease and the associated burden. 
     SUMMARY OF THE DISCLOSURE 
     Following effective therapy of chronic psoriasis, a subclinical inflammation may continue in psoriatic skin that may become clinical once treatment is stopped, e.g., during or after a “drug holiday”. A possible explanation for this phenomenon can be found in the identification of a T-cell subset called tissue resident memory T cells (Trm) that has been proven to contribute to a tissue-localized immunological memory to viral infections of the skin (e.g., infections with herpes simplex virus). This subtype of T cell may be a key player for generating chronicity of immune-mediated inflammatory or auto-reactive disorders. (Clark, R. (2015) Sci Transl Med; 7(269): 269rv1). 
     A newly published study identifies Trm cells in the lesional skin of patients with psoriasis, which remain in the skin after resolution of lesions during treatment with biologic therapy (Cheuk et al (2014) J Immunol; 192(7):3111-20). The presence of these cells in the skin may explain the chronicity of the disease and the reoccurrence of relapses to the same anatomic locations. Cheuk et al (2014) also showed that Trm cells in the psoriatic plaques produce interleukin (IL)-17A and IL-22 upon activation, supporting the notion of Trm cells in psoriasis as Th17 cells with IL-17A as a key effector cytokine. In addition to the direct pathogenic effect of IL-17A from T cells on keratinocytes, IL-17A is also released by granulocytes and mast cells and plays an important role in early attracting more immune cells to the target organ. Therefore, inhibition of IL-17A early after disease onset is a novel and important therapeutic approach to interfering with the immune system before the establishment of extensive and chronic inflammation. This would be achieved by early blocking of the recruitment of inflammatory cells to the skin, including Th17, as well as by blocking the key effector functions of Trm cells. 
     Secukinumab is the first IL-17A inhibitor approved for the treatment of psoriasis in patients requiring systemic treatment. Early treatment of psoriasis patients with IL-17 antagonists, such as secukinumab, in new-onset moderate to severe psoriasis is expected to block recruitment of inflammatory cells and antagonize the effect of IL-17A produced by a subset of T cells. The expected clinical outcome is a change in the natural course of the disease to a milder state by hindering spreading of psoriasis (Trm cells) to new anatomical locations or ultimately totally hindering reoccurrence of new lesions, i.e., inducing minimal, or no, disease activity. 
     Accordingly, disclosed herein are methods of treating a patient having new-onset plaque-type psoriasis, comprising administering a therapeutically effective amount of an IL-17 antagonist to a patient in need thereof. 
     Additionally disclosed herein are methods of, and IL-17 antagonists for use in, decreasing the number of tissue resident memory T-cells in the skin of a patient having new-onset plaque-type psoriasis, decreasing the number of subset effector T-cells producing IL-17 and/or IL-22 in the skin of a patient having new-onset plaque-type psoriasis, decreasing the number of regulatory T-cells in the skin of a patient having new-onset plaque-type psoriasis, decreasing the number of dermal dendritic cell-Tcell aggregates in the skin of a patient having new-onset plaque-type psoriasis, modulating the immune mechanisms causing psoriasis disease chronicity in the skin of a patient having new-onset plaque-type psoriasis, slowing psoriasis disease progression in a patient having new-onset plaque-type psoriasis, decreasing the severity of psoriasis flares in a patient having new-onset plaque-type psoriasis, decreasing the frequency of psoriasis flares in a patient having new-onset plaque-type psoriasis, and/or preventing psoriasis flares in a patient having new-onset plaque-type psoriasis, comprising administering an IL-17 antibody or antigen-binding fragment thereof to a patient in need thereof. 
     In some embodiments of the disclosed uses, methods and kits, the IL-17 antagonist is an IL-17 antibody or antigen-binding fragment thereof. In some embodiments of the disclosed uses, methods and kits, the IL-17 antibody or antigen-binding fragment thereof is selected from the group consisting of: a) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of human IL-17 comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129; b) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of human IL-17 comprising Tyr43, Tyr44, Arg46, Ala79, Asp80; c) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain; d) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 23 to about 35 days; and e) an IL-17 antibody or antigen-binding fragment thereof comprising: i) an immunoglobulin heavy chain variable domain (V H ) comprising the amino acid sequence set forth as SEQ ID NO:8; ii) an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence set forth as SEQ ID NO:10; iii) an immunoglobulin V H  domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V L  domain comprising the amino acid sequence set forth as SEQ ID NO:10; iv) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; v) an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; vi) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13; vii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; viii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; ix) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14; x) an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or xi) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15. In some embodiments of the disclosed uses, methods and kits, the IL-17 antibody or antigen-binding fragment thereof is a human or humanized antibody. In some embodiments of the disclosed uses, methods and kits, the IL-17 antibody or antigen-binding fragment thereof is secukinumab. 
    
    
     
       BRIEF DESCRIPTION OF THE FIGURES 
         FIG. 1 . Treatment with anti-IL-17 Ab, dosed at 100 mg/kg i.p. on days −3, 0, 4, 7 and 11, inhibited skin swelling AUC [0-14 days]  by 22.94±12.25%. 
         FIG. 2 . Treatment with anti-IL-17 Ab, dosed at 100 mg/kg s.c. on day −3 only, inhibited the ear swelling AUC [0-10 days]  by 25.50±2.28%. *p&lt;0.05, unpaired t-test. 
         FIG. 3 . Treatment with anti-IL-17 Ab, dosed at 30 mg/kg i.p. on day −1 only, inhibited the ear swelling AUC [0-8 days]  by 38.57±3.98%. ***p&lt;0.001, paired t-test. 
         FIG. 4 . CAIN457A2322 Trial Design 
         FIG. 5 . Shows percentages of PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response (non-responder imputation) at week 52 by disease duration (Full analysis set). Clinical Trials: CAIN457A2302 and CAIN457A2303; Treatment: secukinumab 150 mg. 
         FIG. 6 . Shows percentages of PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response (non-responder imputation) at week 52 by disease duration (Full analysis set). Clinical Trials: CAIN457A2302 and CAIN457A2303; Treatment: secukinumab 300 mg. 
     
    
    
     DETAILED DESCRIPTION OF THE DISCLOSURE 
     As used herein, IL-17 refers to interleukin-17A (IL-17A). 
     The term “comprising” encompasses “including” as well as “consisting,” e.g., a composition “comprising” X may consist exclusively of X or may include something additional, e.g., X+Y. 
     The term “about” in relation to a numerical value x means, for example, +/−10%. When used in front of a numerical range or list of numbers, the term “about” applies to each number in the series, e.g., the phrase “about 1-5” should be interpreted as “about 1-about 5”, or, e.g., the phrase “about 1, 2, 3, 4” should be interpreted as “about 1, about 2, about 3, about 4, etc.” 
     The word “substantially” does not exclude “completely,” e.g., a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the definition of the disclosure. 
     The term “antibody” as referred to herein includes naturally-occurring and whole antibodies. A naturally-occurring “antibody” is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V H ) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The V H  and V L  regions can be further subdivided into regions of hypervariability, termed hypervariable regions or complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V H  and V L  is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. Exemplary antibodies include secukinumab (Table 1), antibody XAB4 (U.S. Pat. No. 9,193,788), and ixekizumab (U.S. Pat. No. 7,838,638), the disclosures of which are incorporated by reference herein in their entirety. 
     The term “antigen-binding fragment” of an antibody, as used herein, refers to fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., IL-17). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include a Fab fragment, a monovalent fragment consisting of the V L , V H , CL and CH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the V H  and CH1 domains; a Fv fragment consisting of the V L  and V H  domains of a single arm of an antibody; a dAb fragment (Ward et al., 1989 Nature 341:544-546), which consists of a V H  domain; and an isolated CDR. Exemplary antigen-binding fragments include the CDRs of secukinumab as set forth in SEQ ID NOs: 1-6 and 11-13 (Table 1), preferably the heavy chain CDR3. Furthermore, although the two domains of the Fv fragment, V L  and V H , are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L  and V H  regions pair to form monovalent molecules (known as single chain Fv (scFv); see, e.g., Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antibody”. Single chain antibodies and antigen-binding portions are obtained using conventional techniques known to those of skill in the art. 
     An “isolated antibody”, as used herein, refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds IL-17 is substantially free of antibodies that specifically bind antigens other than IL-17). The term “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. The term “human antibody”, as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. A “human antibody” need not be produced by a human, human tissue or human cell. The human antibodies of the disclosure may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, by N-nucleotide addition at junctions in vivo during recombination of antibody genes, or by somatic mutation in vivo). In some embodiments of the disclosed processes and compositions, the IL-17 antibody is a human antibody, an isolated antibody, and/or a monoclonal antibody. 
     The term “IL-17” refers to IL-17A, formerly known as CTLA8, and includes wild-type IL-17A from various species (e.g., human, mouse, and monkey), polymorphic variants of IL-17A, and functional equivalents of IL-17A. Functional equivalents of IL-17A according to the present disclosure preferably have at least about 65%, 75%, 85%, 95%, 96%, 97%, 98%, or even 99% overall sequence identity with a wild-type IL-17A (e.g., human IL-17A), and substantially retain the ability to induce IL-6 production by human dermal fibroblasts. 
     The term “K D ” is intended to refer to the dissociation rate of a particular antibody-antigen interaction. The term “K D ”, as used herein, is intended to refer to the dissociation constant, which is obtained from the ratio of K d  to K a  (i.e., K d /K a ) and is expressed as a molar concentration (M). K D  values for antibodies can be determined using methods well established in the art. A preferred method for determining the K D  of an antibody is by using surface plasmon resonance, or using a biosensor system such as a Biacore® system. In some embodiments, the IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab, binds human IL-17 with a K D  of about 100-250 pM. 
     The term “affinity” refers to the strength of interaction between antibody and antigen at single antigenic sites. Within each antigenic site, the variable region of the antibody “arm” interacts through weak non-covalent forces with antigen at numerous sites; the more interactions, the stronger the affinity. Standard assays to evaluate the binding affinity of the antibodies toward IL-17 of various species are known in the art, including for example, ELISAs, western blots and RIAs. The binding kinetics (e.g., binding affinity) of the antibodies also can be assessed by standard assays known in the art, such as by Biacore analysis. 
     An antibody that “inhibits” one or more of these IL-17 functional properties (e.g., biochemical, immunochemical, cellular, physiological or other biological activities, or the like) as determined according to methodologies known to the art and described herein, will be understood to relate to a statistically significant decrease in the particular activity relative to that seen in the absence of the antibody (or when a control antibody of irrelevant specificity is present). An antibody that inhibits IL-17 activity affects a statistically significant decrease, e.g., by at least about 10% of the measured parameter, by at least 50%, 80% or 90%, and in certain embodiments of the disclosed methods and compositions, the IL-17 antibody used may inhibit greater than 95%, 98% or 99% of IL-17 functional activity. 
     “Inhibit IL-6” as used herein refers to the ability of an IL-17 antibody or antigen-binding fragment thereof (e.g., secukinumab) to decrease IL-6 production from primary human dermal fibroblasts. The production of IL-6 in primary human (dermal) fibroblasts is dependent on IL-17 (Hwang et al., (2004) Arthritis Res Ther; 6:R120-128). In short, human dermal fibroblasts are stimulated with recombinant IL-17 in the presence of various concentrations of an IL-17 binding molecule or human IL-17 receptor with Fc part. The chimeric anti-CD25 antibody Simulect® (basiliximab) may be conveniently used as a negative control. Supernatant is taken after 16 h stimulation and assayed for IL-6 by ELISA. An IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab, typically has an IC 50  for inhibition of IL-6 production (in the presence 1 nM human IL-17) of about 50 nM or less (e.g., from about 0.01 to about 50 nM) when tested as above, i.e., said inhibitory activity being measured on IL-6 production induced by hu-IL-17 in human dermal fibroblasts. In some embodiments of the disclosed methods and compositions, IL-17 antibodies or antigen-binding fragments thereof, e.g., secukinumab, and functional derivatives thereof have an IC 50  for inhibition of IL-6 production as defined above of about 20 nM or less, more preferably of about 10 nM or less, more preferably of about 5 nM or less, more preferably of about 2 nM or less, more preferably of about 1 nM or less. 
     The term “derivative”, unless otherwise indicated, is used to define amino acid sequence variants, and covalent modifications (e.g., pegylation, deamidation, hydroxylation, phosphorylation, methylation, etc.) of an IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab, according to the present disclosure, e.g., of a specified sequence (e.g., a variable domain). A “functional derivative” includes a molecule having a qualitative biological activity in common with the disclosed IL-17 antibodies. A functional derivative includes fragments and peptide analogs of an IL-17 antibody as disclosed herein. Fragments comprise regions within the sequence of a polypeptide according to the present disclosure, e.g., of a specified sequence. Functional derivatives of the IL-17 antibodies disclosed herein (e.g., functional derivatives of secukinumab) preferably comprise V H  and/or V L  domains that have at least about 65%, 75%, 85%, 95%, 96%, 97%, 98%, or even 99% overall sequence identity with the V H  and/or V L  sequences of the IL-17 antibodies and antigen-binding fragments thereof disclosed herein (e.g., the V H  and/or V L  sequences of Table 1), and substantially retain the ability to bind human IL-17 or, e.g., inhibit IL-6 production of IL-17 induced human dermal fibroblasts. 
     The phrase “substantially identical” means that the relevant amino acid or nucleotide sequence (e.g., V H  or V L  domain) will be identical to or have insubstantial differences (e.g., through conserved amino acid substitutions) in comparison to a particular reference sequence. Insubstantial differences include minor amino acid changes, such as 1 or 2 substitutions in a 5 amino acid sequence of a specified region (e.g., V H  or V L  domain). In the case of antibodies, the second antibody has the same specificity and has at least 50% of the affinity of the same. Sequences substantially identical (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiments, the sequence identity of a derivative IL-17 antibody (e.g., a derivative of secukinumab, e.g., a secukinumab biosimilar antibody) can be about 90% or greater, e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher relative to the disclosed sequences. 
     “Identity” with respect to a native polypeptide and its functional derivative is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions nor insertions shall be construed as reducing identity. Methods and computer programs for the alignment are well known. The percent identity can be determined by standard alignment algorithms, for example, the Basic Local Alignment Search Tool (BLAST) described by Altshul et al. ((1990) J. Mol. Biol., 003 410); the algorithm of Needleman et al. ((1970) J. Mol. Biol., 48: 444 453); or the algorithm of Meyers et al. ((1988) Comput. Appl. Biosci., 4: 11 17). A set of parameters may be the Blosum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. “Amino acid(s)” refer to all naturally occurring L-a-amino acids, e.g., and include D-amino acids. The phrase “amino acid sequence variant” refers to molecules with some differences in their amino acid sequences as compared to the sequences according to the present disclosure. Amino acid sequence variants of an antibody according to the present disclosure, e.g., of a specified sequence, still have the ability to bind the human IL-17 or, e.g., inhibit IL-6 production of IL-17 induced human dermal fibroblasts. Amino acid sequence variants include substitutional variants (those that have at least one amino acid residue removed and a different amino acid inserted in its place at the same position in a polypeptide according to the present disclosure), insertional variants (those with one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a polypeptide according to the present disclosure) and deletional variants (those with one or more amino acids removed in a polypeptide according to the present disclosure). 
     The term “pharmaceutically acceptable” means a nontoxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). 
     The term “administering” in relation to a compound, e.g., an IL-17 binding molecule or another agent, is used to refer to delivery of that compound to a patient by any route. 
     As used herein, a “therapeutically effective amount” refers to an amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof) that is effective, upon single or multiple dose administration to a patient (such as a human) for treating, preventing, preventing the onset of, curing, delaying, reducing the severity of, ameliorating at least one symptom of a disorder or recurring disorder, or prolonging the survival of the patient beyond that expected in the absence of such treatment. When applied to an individual active ingredient (e.g., an IL-17 antagonist, e.g., secukinumab) administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. 
     The term “treatment” or “treat” is herein defined as the application or administration of an IL-17 antibody according to the disclosure, for example, secukinumab or ixekizumab, or a pharmaceutical composition comprising said anti-IL-17 antibody, to a subject or to an isolated tissue or cell line from a subject, where the subject has a particular disease (e.g., psoriasis), a symptom associated with the disease (e.g., psoriasis), or a predisposition towards development of the disease (e.g., psoriasis), where the purpose is to cure (if applicable), delay the onset of, reduce the severity of, alleviate, ameliorate one or more symptoms of the disease, improve the disease, reduce or improve any associated symptoms of the disease or the predisposition toward the development of the disease. The term “treatment” or “treat” includes treating a patient suspected to have the disease as well as patients who are ill or who have been diagnosed as suffering from the disease or medical condition, and includes suppression of clinical relapse. 
     As used herein, the phrase “new-onset plaque-type psoriasis” is used to mean plaque-type psoriasis in which the first psoriasis plaque appeared (debuted) within 12 months (&lt;12 months) prior to the start of treatment with the IL-17 antagonist (e.g., secukinumab). 
     As used herein, the phrases “has not been previously treated with a systemic treatment for psoriasis” and “naive” refer to a psoriasis patient who has not been previously treated with a systemic agent, e.g., methotrexate, cyclosporine, a biological (e.g., ustekinumab, infliximab, TNF alpha inhibitors, etc.), etc., for psoriasis. Systemic agents (i.e., agents given orally, by injection, etc.) differ from local agents (e.g., topicals and phototherapy) in that systemic agents have a systemic effect when delivered to a patient. As used herein, the phrase “has not been previously treated with phototherapy for psoriasis” refers to a psoriasis patient who has not been previously treated with narrow band-UVB (nb-UVB) for psoriasis. In some embodiments of the disclosed methods, regimens, uses, kits, and pharmaceutical compositions, the patient has not been previously treated with a systemic treatment for psoriasis. In some embodiments of the disclosed methods, regimens, uses, kits, and pharmaceutical compositions, the patient has not been previously treated with phototherapy for psoriasis. 
     As used herein, the phrases “has been previously treated with a systemic agent for psoriasis” is used to mean a patient that has previously undergone psoriasis treatment using a systemic agent. Such patients include those previously treated with biologics, such as ustekinumab, and those previously treated with non-biologics, such as cyclosporine. In some embodiments of the disclosure, the patient has been previously treated with a systemic agent for psoriasis. 
     In some embodiments, the patient has been previously treated with a systemic agent for psoriasis (e.g., methotrexate, cyclosporine), but the patient has not been previously treated with a systemic biological drug (i.e., a drug produced by a living organism, e.g., antibodies, receptor decoys, etc.) for psoriasis (e.g., ustekinumab, ixekizumab, broadalumab, TNF alpha inhibitors (etanercept, adalimumab, remicade, etc.), secukinumab, etc.). In this case, the patient is referred to as “biological-naïve.” In preferred embodiments, the patient is biological-naïve. 
     As used herein, the term “TNF failure” refers to a patient who had an inadequate response to or was intolerant to prior treatment with a TNF alpha antagonist (e.g., etanercept, adalimumab, etc.). A patient who has responded adequately to prior treatment with a TNF alpha antagonist (e.g., etanercept, adalimumab, etc.) but has discontinued due to a side effect is termed “intolerant”. TNF failures are also sometimes referred to as “TNF-IR” patients. In some embodiments, prior to administering the IL-17 antagonist, the patient is a TNF failure. 
     As used herein, “selecting” and “selected” in reference to a patient is used to mean that a particular patient is specifically chosen from a larger group of patients on the basis of (due to) the particular patient having a predetermined criteria. Similarly, “selectively treating” refers to providing treatment to a patient having a particular disease, where that patient is specifically chosen from a larger group of patients on the basis of the particular patient having a predetermined criterion. Similarly, “selectively administering” refers to administering a drug to a patient that is specifically chosen from a larger group of patients on the basis of (due to) the particular patient having a predetermined criterion. By selecting, selectively treating and selectively administering, it is meant that a patient is delivered a personalized therapy based on the patient&#39;s personal history (e.g., prior therapeutic interventions, e.g., prior treatment with biologics), biology (e.g., particular genetic markers), and/or manifestation (e.g., not fulfilling particular diagnostic criteria), rather than being delivered a standard treatment regimen based solely on the patient&#39;s membership in a larger group. Selecting, in reference to a method of treatment as used herein, does not refer to fortuitous treatment of a patient having a particular criterion, but rather refers to the deliberate choice to administer treatment to a patient based on the patient having a particular criterion. Thus, selective treatment/administration differs from standard treatment/administration, which delivers a particular drug to all patients having a particular disease, regardless of their personal history, manifestations of disease, and/or biology. In some embodiments, the patient is selected for treatment based on having new-onset plaque-type psoriasis. 
     As used herein, the phrase “tissue resident memory T cells in the skin” refers to non-recirculating memory T cells that persist in the epidermis. (See, e.g., Clark (2015), supra). In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) reduces tissue resident memory T-cells in the skin. 
     As used herein, the phrase “subset effector T cells producing interleukin-17 (IL-17) and/or interleukin-22 (IL-22) in the skin” means epidermal CD4 and CD8 T cells that produce IL-17 and IL-22. (See, e.g., Clark (2015), supra). In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) reduces subset effector T-cells producing interleukin-17 (IL-17) and/or interleukin-22 (IL-22) in the skin. 
     As used herein, the phrase “regulatory T cells in the skin” refers to a population of T cells, characterized by expression of the transcription factor Foxp3, found in skin. (See, e.g., Sanchez Rodriguez et al. (2014) J. Clin. Invest. 124(3):1027-1036). In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) reduces and normalizes the number of regulatory T cells in the skin. 
     As used herein, the phrase “dermal dendritic cell-T cell aggregates in the skin” refers to dermal clusters comprising dendritic cells and infiltrating T cells. (See, e.g., Kim et al. (2014) J. Invest. Derm. 134(5):1462-65). In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) reduces dermal dendritic cell-T cell aggregates in the skin. 
     Collectively, the acts of reducing tissue resident memory T-cells in the skin, reducing subset effector T-cells producing interleukin-17 (IL-17) and/or interleukin-22 (IL-22) in the skin, reducing regulatory T cells in the skin, and reducing dermal dendritic cell-T cell aggregates in the skin (e.g., reducing cell-mediated immunity in the skin, reducing T-cell-mediated immune response in the skin) is referred to herein as “modulating the immune mechanisms causing psoriasis disease chronicity.” In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) modulates the immune mechanisms causing psoriasis disease chronicity. 
     The plaque psoriasis disease course begins with small skin plaques ˜⅛ of an inch wide, typically in the same areas on opposite sides of the body. They grow slowly and develop into thick, dry plaques. If the plaque is scratched or scraped, bleeding spots the sizes of pinheads appear underneath. This is known as the Auspitz sign. Some patches become annular, with a clear center and scaly raised borders. Eventually, separate patches join together to form larger areas. In some cases, the patches cover wide areas of the back or chest, termed geographic plaques. As used herein, the phrase “slowing psoriasis disease progression” means decelerating the advancement rate of the disease course of plaque-type psoriasis. In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) slows psoriasis disease progression. 
     As used herein, the phrase “psoriasis flare” comprises the manifestation of plaque-type psoriasis, including plaques, irritated patches of skin, redness (e.g., particularly on elbows, knees, trunk and scalp), changes and/or disfiguration in nails, dandruff, and any combination thereof. Typically, a psoriasis flare includes the formation of psoriasis plaques. In some embodiments of the disclosure, treatment with the IL-17 antagonist (e.g., secukinumab) prevents psoriasis flares, decreases the severity of psoriasis flares, and/or decreases the frequency of psoriasis flares. 
     As used herein, the phrase “decreasing the severity of psoriasis flares” and the like means reducing the intensity of a psoriasis flare, e.g., reducing the percentage of skin affected by psoriasis, reducing the intensity of a particular flare component (e.g., reducing the number, size, thickness, etc. of plaques, reducing the extent of skin irritation, reducing scaling, reducing erythema, reducing changes and/or disfigurations in nails, reducing dandruff, etc.), and/or reducing the amount of time a flare (or component thereof) persists. The severity of a flare may be measured using various tools, e.g., the body surface area (BSA) test, the investigator&#39;s global assessment (IGA, IGA mod 2011), physicians global assessment (PGA), the psoriasis area and severity index (PASI), and patient reported outcomes, e.g., the Dermatology life quality index (DLQI) and the Work productivity and activity impairment questionnaire: psoriasis (WPAI:PSO). In some embodiments of the disclosed methods, kits, and uses, the patient achieves at least a 50% reduction of the Psoriasis Area and Severity Index Score (PASI 50) at week 12 of treatment. In some embodiments of the disclosed methods, kits, and uses, the patient achieves at least a 75% reduction of the Psoriasis Area and Severity Index Score (PASI 75) at week 12 of treatment. In some embodiments of the disclosed methods, kits, and uses, the patient achieves at least a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 12 of treatment. In some embodiments of the disclosed methods, kits, and uses, the patient achieves 100% reduction of the Psoriasis Area and Severity Index Score (PASI 100) at week 12 of treatment. 
     As used herein, the phrase “decreasing the frequency of psoriasis flares” and the like means reducing the incidence of psoriasis flares, e.g., reducing the incidence of plaques and/or other psoriasis flare components (e.g., plaques, skin irritation, scaling, erythema, changes in nails, dandruff, etc.). By decreasing the frequency of psoriasis flares, a patient will experience fewer psoriasis relapses. The incidence of flares may be assessed by monitoring a patient over time to determine if the prevalence of flares decreases. 
     As used herein, the phrase “preventing psoriasis flares” means eliminating future psoriasis flares and/or flare components. 
     Numerous psoriasis patients eventually progress to psoriatic arthritis (PsA). Treatment of new-onset psoriasis patients with an IL-17 antagonist (e.g., an IL-17 antibody, like secukinumab) is expected to decrease the likelihood that these patients will eventually develop PsA, cardiovascular disease, metabolic syndrome (diabetes mellitus, obesity), and other conditions. As used herein, the phrase “decreasing the likelihood that a psoriasis patient will develop psoriatic arthritis” refers to a reduction in the probability that a psoriasis patient will develop psoriatic arthritis. As used herein, the phrase “delaying the onset of psoriatic arthritis in a psoriasis patient” refers to postponing development of the signs and symptoms, and/or structural damage associated with PsA in a psoriasis patient. As used herein, the phrase “preventing progression from psoriasis to psoriatic arthritis in a psoriasis patient” refers to inhibiting the development of PsA in a psoriasis patient. 
     As used herein “mild psoriasis” is defined as psoriasis disease in which body surface area (BSA) ≤10 and psoriasis area and severity index (PASI) &lt;10 and dermatology life quality index (DLQI) ≤10. As used herein, “moderate to severe psoriasis” is defined as psoriasis disease in which (BSA &gt;10 or PASI &gt;10) and DLQI &gt;10. See Mrowietz et al. (2011) Arch Dermatol Res. 303(1):1-10. In some embodiments of the disclosed methods, uses and kits, the patient has mild psoriasis. In some embodiments of the disclosed methods, uses and kits, the patient has moderate to severe psoriasis. In some embodiments of the disclosed methods, uses and kits, long-term treatment with the IL-17 antagonist (e.g., IL-17 antibody, such as secukinumab) patient converts from having moderate to severe psoriasis to having mild psoriasis due to a modification of the psoriasis disease course. 
     In a preferred embodiment, the methods and uses disclosed herein provide treatment of moderate to severe chronic plaque-type psoriasis in adult patients who are candidates for systemic therapy (or phototherapy). In some embodiments, the adult patient who is a candidate for systemic therapy (or phototherapy) has a BSA ≥5%. In some embodiments, the adult patient who is a candidate for systemic therapy (or phototherapy) has a BSA ≥3%. 
     IL-17 Antagonists 
     The various disclosed processes, kits, uses and methods utilize an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., soluble IL-17 receptor, IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof). In some embodiments, the IL-17 antagonist is an IL-17 binding molecule, preferably an IL-17 antibody or antigen-binding fragment thereof. 
     In one embodiment, the IL-17 antibody or antigen-binding fragment thereof comprises at least one immunoglobulin heavy chain variable domain (V H ) comprising hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3. In one embodiment, the IL-17 antibody or antigen-binding fragment thereof comprises at least one immunoglobulin light chain variable domain (V L ′) comprising hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence SEQ ID NO:4, said CDR2′ having the amino acid sequence SEQ ID NO:5 and said CDR3′ having the amino acid sequence SEQ ID NO:6. In one embodiment, the IL-17 antibody or antigen-binding fragment thereof comprises at least one immunoglobulin heavy chain variable domain (V H ) comprising hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO:11, said CDR2-x having the amino acid sequence SEQ ID NO:12, and said CDR3-x having the amino acid sequence SEQ ID NO:13. 
     In one embodiment, the IL-17 antibody or antigen-binding fragment thereof comprises at least one immunoglobulin V H  domain and at least one immunoglobulin V L  domain, wherein: a) the immunoglobulin V H  domain comprises (e.g., in sequence): i) hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3; or ii) hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO:11, said CDR2-x having the amino acid sequence SEQ ID NO:12, and said CDR3-x having the amino acid sequence SEQ ID NO:13; and b) the immunoglobulin V L  domain comprises (e.g., in sequence) hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence SEQ ID NO:4, said CDR2′ having the amino acid sequence SEQ ID NO:5, and said CDR3′ having the amino acid sequence SEQ ID NO:6. 
     In one embodiment, the IL-17 antibody or antigen-binding fragment thereof comprises: a) an immunoglobulin heavy chain variable domain (V H ) comprising the amino acid sequence set forth as SEQ ID NO:8; b) an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence set forth as SEQ ID NO:10; c) an immunoglobulin V H  domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V L  domain comprising the amino acid sequence set forth as SEQ ID NO:10; d) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; e) an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; f) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13; g) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or h) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. 
     For ease of reference the amino acid sequences of the hypervariable regions of the secukinumab monoclonal antibody, based on the Kabat definition and as determined by the X-ray analysis and using the approach of Chothia and coworkers, is provided in Table 1, below. 
     
       
         
           
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Amino acid sequences of the hypervariable 
               
               
                 regions of secukinumab. 
               
               
                   
               
             
            
               
                 Light-Chain 
               
            
           
           
               
               
               
               
            
               
                   
                 CDR1′ 
                 Kabat 
                 R-A-S-Q-S-V-S-S-S-Y-L-A 
               
               
                   
                   
                   
                 (SEQ ID NO: 4) 
               
               
                   
                   
               
               
                   
                   
                 Chothia 
                 R-A-S-Q-S-V-S-S-S-Y-L-A 
               
               
                   
                   
                   
                 (SEQ ID NO: 4) 
               
               
                   
                   
               
               
                   
                 CDR2′ 
                 Kabat 
                 G-A-S-S-R-A-T 
               
               
                   
                   
                   
                 (SEQ ID NO: 5) 
               
               
                   
                   
               
               
                   
                   
                 Chothia 
                 G-A-S-S-R-A-T 
               
               
                   
                   
                   
                 (SEQ ID NO: 5) 
               
               
                   
                   
               
               
                   
                 CDR2′ 
                 Kabat 
                 Q-Q-Y-G-S-S-P-C-T 
               
               
                   
                   
                   
                 (SEQ ID NO: 6) 
               
               
                   
                   
               
               
                   
                   
                 Chothia 
                 Q-Q-Y-G-S-S-P-C-T 
               
               
                   
                   
                   
                 (SEQ ID NO: 6) 
               
               
                   
                   
               
            
           
           
               
            
               
                 Heavy-Chain 
               
            
           
           
               
               
               
               
            
               
                   
                 CDR1 
                 Kabat 
                 N-Y-W-M-N 
               
               
                   
                   
                   
                 (SEQ ID NO: 1) 
               
               
                   
                   
               
               
                   
                 CDR1-x 
                 Chothia 
                 G-F-T-F-S-N-Y-W-M-N 
               
               
                   
                   
                   
                 (SEQ ID NO: 11) 
               
               
                   
                   
               
               
                   
                 CDR2 
                 Kabat 
                 A-I-N-Q-D-G-S-E-K-Y-Y-V- 
               
               
                   
                   
                   
                 G-S-V-K-G 
               
               
                   
                   
                   
                 (SEQ ID NO: 2) 
               
               
                   
                   
               
               
                   
                 CDR2-x 
                 Chothia 
                 A-I-N-Q-D-G-S-E-K-Y-Y 
               
               
                   
                   
                   
                 (SEQ ID NO: 12) 
               
               
                   
                   
               
               
                   
                 CDR3 
                 Kabat 
                 D-Y-Y-D-I-L-T-D-Y-Y-I-H- 
               
               
                   
                   
                   
                 Y-W-Y-F-D-L 
               
               
                   
                   
                   
                 (SEQ ID NO: 3) 
               
               
                   
                   
               
               
                   
                 CDR3-x 
                 Chothia 
                 C-V-R-D-Y-Y-D-I-L-T-D-Y- 
               
               
                   
                   
                   
                 Y-I-H-Y-W-Y-F-D-L-W-G 
               
               
                   
                   
                   
                 (SEQ ID NO: 13) 
               
               
                   
                   
               
            
           
         
       
     
     In preferred embodiments, constant region domains also comprise suitable human constant region domains, for instance as described in “Sequences of Proteins of Immunological Interest”, Kabat E. A. et al, US Department of Health and Human Services, Public Health Service, National Institute of Health. The DNA encoding the VL of secukinumab is set forth in SEQ ID NO:9. The DNA encoding the V H  of secukinumab is set forth in SEQ ID NO:7. 
     In some embodiments, the IL-17 antibody or antigen-binding fragment thereof (e.g., secukinumab) comprises the three CDRs of SEQ ID NO:10. In other embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the three CDRs of SEQ ID NO:8. In other embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the three CDRs of SEQ ID NO:10 and the three CDRs of SEQ ID NO:8. CDRs of SEQ ID NO:8 and SEQ ID NO:10 may be found in Table 1. The free cysteine in the light chain (CysL97) may be seen in SEQ ID NO:6. 
     In some embodiments, IL-17 antibody or antigen-binding fragment thereof comprises the light chain of SEQ ID NO:14. In other embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the heavy chain of SEQ ID NO:15. In other embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the light chain of SEQ ID NO:14 and the heavy domain of SEQ ID NO:15. In some embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the three CDRs of SEQ ID NO:14. In other embodiments, IL-17 antibody or antigen-binding fragment thereof comprises the three CDRs of SEQ ID NO:15. In other embodiments, the IL-17 antibody or antigen-binding fragment thereof comprises the three CDRs of SEQ ID NO:14 and the three CDRs of SEQ ID NO:15. CDRs of SEQ ID NO:14 and SEQ ID NO:15 may be found in Table 1. 
     Hypervariable regions may be associated with any kind of framework regions, though preferably are of human origin. Suitable framework regions are described in Kabat E. A. et al, ibid. The preferred heavy chain framework is a human heavy chain framework, for instance that of the secukinumab antibody. It consists in sequence, e.g. of FR1 (amino acid 1 to 30 of SEQ ID NO:8), FR2 (amino acid 36 to 49 of SEQ ID NO:8), FR3 (amino acid 67 to 98 of SEQ ID NO:8) and FR4 (amino acid 117 to 127 of SEQ ID NO:8) regions. Taking into consideration the determined hypervariable regions of secukinumab by X-ray analysis, another preferred heavy chain framework consists in sequence of FR1-x (amino acid 1 to 25 of SEQ ID NO:8), FR2-x (amino acid 36 to 49 of SEQ ID NO:8), FR3-x (amino acid 61 to 95 of SEQ ID NO:8) and FR4 (amino acid 119 to 127 of SEQ ID NO:8) regions. In a similar manner, the light chain framework consists, in sequence, of FR1′ (amino acid 1 to 23 of SEQ ID NO:10), FR2′ (amino acid 36 to 50 of SEQ ID NO:10), FR3′ (amino acid 58 to 89 of SEQ ID NO:10) and FR4′ (amino acid 99 to 109 of SEQ ID NO:10) regions. 
     In one embodiment, the IL-17 antibody or antigen-binding fragment thereof (e.g., secukinumab) is selected from a human IL-17 antibody that comprises at least: a) an immunoglobulin heavy chain or fragment thereof which comprises a variable domain comprising, in sequence, the hypervariable regions CDR1, CDR2 and CDR3 and the constant part or fragment thereof of a human heavy chain; said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3; and b) an immunoglobulin light chain or fragment thereof which comprises a variable domain comprising, in sequence, the hypervariable regions CDR1′, CDR2′, and CDR3′ and the constant part or fragment thereof of a human light chain, said CDR1′ having the amino acid sequence SEQ ID NO:4, said CDR2′ having the amino acid sequence SEQ ID NO:5, and said CDR3′ having the amino acid sequence SEQ ID NO:6. 
     In one embodiment, the IL-17 antibody or antigen-binding fragment thereof is selected from a single chain antibody or antigen-binding fragment thereof that comprises an antigen-binding site comprising: a) a first domain comprising, in sequence, the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3; and b) a second domain comprising, in sequence, the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence SEQ ID NO:4, said CDR2′ having the amino acid sequence SEQ ID NO:5, and said CDR3′ having the amino acid sequence SEQ ID NO:6; and c) a peptide linker which is bound either to the N-terminal extremity of the first domain and to the C-terminal extremity of the second domain or to the C-terminal extremity of the first domain and to the N-terminal extremity of the second domain. 
     Alternatively, an IL-17 antibody or antigen-binding fragment thereof as used in the disclosed methods may comprise a derivative of the IL-17 antibodies set forth herein by sequence (e.g., a pegylated version of secukinumab). Alternatively, the V H  or V L  domain of an IL-17 antibody or antigen-binding fragment thereof used in the disclosed methods may have V H  or V L  domains that are substantially identical to the V H  or V L  domains set forth herein (e.g., those set forth in SEQ ID NO:8 and 10). A human IL-17 antibody disclosed herein may comprise a heavy chain that is substantially identical to that set forth as SEQ ID NO:15 and/or a light chain that is substantially identical to that set forth as SEQ ID NO:14. A human IL-17 antibody disclosed herein may comprise a heavy chain that comprises SEQ ID NO:15 and a light chain that comprises SEQ ID NO:14. A human IL-17 antibody disclosed herein may comprise: a) one heavy chain which comprises a variable domain having an amino acid sequence substantially identical to that shown in SEQ ID NO:8 and the constant part of a human heavy chain; and b) one light chain which comprises a variable domain having an amino acid sequence substantially identical to that shown in SEQ ID NO:10 and the constant part of a human light chain. 
     Alternatively, an IL-17 antibody or antigen-binding fragment thereof used in the disclosed methods may be an amino acid sequence variant of the reference IL-17 antibodies set forth herein, as long as it contains CysL97. The disclosure also includes IL-17 antibodies or antigen-binding fragments thereof (e.g., secukinumab) in which one or more of the amino acid residues of the V H  or V L  domain of secukinumab (but not CysL97), typically only a few (e.g., 1-10), are changed; for instance by mutation, e.g., site directed mutagenesis of the corresponding DNA sequences. In all such cases of derivative and variants, the IL-17 antibody or antigen-binding fragment thereof is capable of inhibiting the activity of about 1 nM (=30 ng/ml) human IL-17 at a concentration of about 50 nM or less, about 20 nM or less, about 10 nM or less, about 5 nM or less, about 2 nM or less, or more preferably of about 1 nM or less of said molecule by 50%, said inhibitory activity being measured on IL-6 production induced by hu-IL-17 in human dermal fibroblasts as described in Example 1 of WO 2006/013107. 
     In some embodiments, the IL-17 antibodies or antigen-binding fragments thereof, e.g., secukinumab, bind to an epitope of mature human IL-17 comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129. In some embodiments, the IL-17 antibody, e.g., secukinumab, binds to an epitope of mature human IL-17 comprising Tyr43, Tyr44, Arg46, Ala79, Asp80. In some embodiments, the IL-17 antibody, e.g., secukinumab, binds to an epitope of an IL-17 homodimer having two mature human IL-17 chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain. The residue numbering scheme used to define these epitopes is based on residue one being the first amino acid of the mature protein (i.e., IL-17A lacking the 23 amino acid N-terminal signal peptide and beginning with Glycine). The sequence for immature IL-17A is set forth in the Swiss-Prot entry Q16552. In some embodiments, the IL-17 antibody has a K D  of about 100-200 pM (e.g., as determined by a Biacore® assay). In some embodiments, the IL-17 antibody has an IC 50  of about 0.4 nM for in vitro neutralization of the biological activity of about 0.67 nM human IL-17A. In some embodiments, the absolute bioavailability of subcutaneously (SC) administered IL-17 antibody has a range of about 60-about 80%, e.g., about 76%. In some embodiments, the IL-17 antibody, such as secukinumab, has an elimination half-life of about 4 weeks (e.g., about 23 to about 35 days, about 23 to about 30 days, e.g., about 30 days). In some embodiments, the IL-17 antibody (such as secukinumab) has a T max  of about 7-8 days. 
     Particularly preferred IL-17 antibodies or antigen-binding fragments thereof used in the disclosed methods are human antibodies, especially secukinumab as described in Examples 1 and 2 of WO 2006/013107. Secukinumab is a recombinant high-affinity, fully human monoclonal anti-human interleukin-17A (IL-17A, IL-17) antibody of the IgG1/kappa isotype that is currently in clinical trials for the treatment of immune-mediated inflammatory conditions. Secukinumab (see, e.g., WO2006/013107 and WO2007/117749) has a very high affinity for IL-17, i.e., a K D  of about 100-200 pM and an IC 50  for in vitro neutralization of the biological activity of about 0.67 nM human IL-17A of about 0.4 nM. Thus, secukinumab inhibits antigen at a molar ratio of about 1:1. This high binding affinity makes the secukinumab antibody particularly suitable for therapeutic applications. Furthermore, it has been determined that secukinumab has a very long half-life, i.e., about 4 weeks, which allows for prolonged periods between administration, an exceptional property when treating chronic life-long disorders, such as psoriasis. 
     Other preferred IL-17 antibodies for use in the disclosed methods, kits and regimens are those set forth in U.S. Pat. Nos. 8,057,794; 8,003,099; 8,110,191; and 7,838,638 and US Published Patent Application Nos: 20120034656 and 20110027290, which are incorporated by reference herein in their entirety. 
     Methods of Treatment and Uses of IL-17 Antagonists for New-Onset Plaque-Type Psoriasis 
     The disclosed IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 receptor antibody or antigen-binding fragment thereof), may be used in vitro, ex vivo, or incorporated into pharmaceutical compositions and administered in vivo to treat new-onset plaque-type psoriasis patients (e.g., human patients). 
     The disclosed IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 receptor antibody or antigen-binding fragment thereof), may be used in vitro, ex vivo, or incorporated into pharmaceutical compositions and administered in vivo to treat pyoderma gangrenosum, ichthyoses, pytiriasis rubra pilaris, rosacea (e.g, papulopustular rosacea), lichen planopilaris, atopic dermatitis, allergic contact dermatitis, alopecia areata, and human papilloma virus (HPV). Preferred dosing and treatment regimens (including both induction and maintenance regimens) for treating these disorders are provided in PCT Application No. PCT/US2011/064307 and PCT/IB2014/063902, which are incorporated by reference herein in their entirety. In some embodiments, the patient is administered about 150 mg-about 300 mg (e.g., preferably about 150 mg or about 300 mg) of the IL-17 antibody or antigen-binding fragment thereof (e.g., preferably secukinumab) by subcutaneous (SC) injection at weeks 0, 1, 2, 3, and 4, followed by once monthly dosing. In some embodiments, the patient is administered about 150 mg-about 300 mg (e.g., preferably about 150 mg or about 300 mg) of the IL-17 antibody or antigen-binding fragment thereof (e.g., preferably secukinumab) by subcutaneous (SC) injection monthly (i.e., week 0, 4, 8, 12, 16). 
     The IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof), may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to an IL-17 antagonist, carriers, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The characteristics of the carrier will depend on the route of administration. The pharmaceutical compositions for use in the disclosed methods may also contain additional therapeutic agents for treatment of the particular targeted disorder. For example, a pharmaceutical composition may also include anti-inflammatory agents. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with the IL-17 binding molecules, or to minimize side effects caused by the IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof). In preferred embodiments, the pharmaceutical compositions for use in the disclosed methods comprise secukinumab at 150 mg/ml. 
     Pharmaceutical compositions for use in the disclosed methods may be manufactured in conventional manner. In one embodiment, the pharmaceutical composition is provided in lyophilized form. For immediate administration it is dissolved in a suitable aqueous carrier, for example sterile water for injection or sterile buffered physiological saline. If it is considered desirable to make up a solution of larger volume for administration by infusion rather than a bolus injection, may be advantageous to incorporate human serum albumin or the patient&#39;s own heparinised blood into the saline at the time of formulation. The presence of an excess of such physiologically inert protein prevents loss of antibody by adsorption onto the walls of the container and tubing used with the infusion solution. If albumin is used, a suitable concentration is from 0.5 to 4.5% by weight of the saline solution. Other formulations comprise liquid or lyophilized formulation. 
     Antibodies, e.g., antibodies to IL-17, are typically formulated either in aqueous form ready for parenteral administration or as lyophilisates for reconstitution with a suitable diluent prior to administration. In some embodiments of the disclosed methods and uses, the IL-17 antagonist, e.g., IL-17 antibody, e.g., secukinumab, is formulated as a lyophilisate. Suitable lyophilisate formulations can be reconstituted in a small liquid volume (e.g., 2 ml or less) to allow subcutaneous administration and can provide solutions with low levels of antibody aggregation. The use of antibodies as the active ingredient of pharmaceuticals is now widespread, including the products HERCEPTIN™ (trastuzumab), RITUXAN™ (rituximab), SYNAGIS™ (palivizumab), etc. Techniques for purification of antibodies to a pharmaceutical grade are well known in the art. When a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof) is administered by intravenous, cutaneous or subcutaneous injection, the IL-17 antagonist will be in the form of a pyrogen-free, parenterally acceptable solution. A pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection may contain, in addition to the IL-17 antagonist, an isotonic vehicle such as sodium chloride, Ringer&#39;s solution, dextrose, dextrose and sodium chloride, lactated Ringer&#39;s solution, or other vehicle as known in the art. 
     The appropriate dosage will vary depending upon, for example, the particular IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof) to be employed, the host, the mode of administration and the nature and severity of the condition being treated, and on the nature of prior treatments that the patient has undergone. Ultimately, the attending health care provider will decide the amount of the IL-17 antagonist with which to treat each individual patient. In some embodiments, the attending health care provider may administer low doses of the IL-17 antagonist and observe the patient&#39;s response. In other embodiments, the initial dose(s) of IL-17 antagonist administered to a patient are high, and then are titrated downward until signs of relapse occur. Larger doses of the IL-17 antagonist may be administered until the optimal therapeutic effect is obtained for the patient, and the dosage is not generally increased further. 
     In practicing some of the methods of treatment or uses of the present disclosure, a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof) is administered to a patient, e.g., a mammal (e.g., a human). While it is understood that the disclosed methods provide for treatment of new-onset plaque-type psoriasis patients using an IL-17 antagonist (e.g., secukinumab), this does not preclude that, if the patient is to be ultimately treated with an IL-17 antagonist, such IL-17 antagonist therapy is necessarily a monotherapy. Indeed, if a patient is selected for treatment with an IL-17 antagonist, then the IL-17 antagonist (e.g., secukinumab) may be administered in accordance with the methods of the disclosure either alone or in combination with other agents and therapies for treating new-onset plaque-type psoriasis patients, e.g., in combination with at least one additional psoriasis agent. When coadministered with one or more additional psoriasis agent(s), an IL-17 antagonist may be administered either simultaneously with the other agent, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering the IL-17 antagonist in combination with other agents and the appropriate dosages for co-delivery. 
     Various therapies may be beneficially combined with the disclosed IL-17 antibodies, such as secukinumab, during treatment of new-onset plaque psoriasis and the other disorders disclosed herein. Such therapies include topicals (over the counter, non-steroidal compounds, and steroidal compound), phototherapy and systemic treatment (e.g., with biologicals or chemical entities). 
     Non-limiting examples of topical psoriasis agents for use with the disclosed IL-17 antibodies, such as secukinumab, include salicylic acid, coal tar, Dovonex® (calcipotriene), Taclonex® (calcipotriene and betamethasone dipropionate), Tazorec® (tazarotene), pimecrolimus, tacrolimus, Vectical® (calcitriol), Zithranol-RR® (anthralin) and topical steroids (e.g., corticosteroids). 
     Examples of phototherapy for use with the disclosed IL-17 antibodies, such as secukinumab, include treatment with psoralen+UVA (PUVA) or treatment with UVB (with or without tar). 
     Examples of psoriasis agents used in systemic treatment for use with the disclosed IL-17 antibodies, such as secukinumab, include retionoids such as Acitretin (e.g., Soriatane®), cyclosporine, methotrexate, hydroxyurea (e.g., Hydrea®), isotretinoin, mycophenolate mofetil, mycophenolic acid, sulfasalazine, 6-thioguanine, fumarates (e. g, dimethylfumarate and fumaric acid esters), azathioprine, corticosteroids, leflunomide, tacrolimus, T-cell blockers (such as Amevive® (alefacept) and Raptiva® (efalizumab), tumor necrosis factor-alpha (TNF-alpha) blockers (such as Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab) and Simponi® (golimumab)) and interleukin 12/23 blockers (such as Stelara® (ustekinumab), tasocitinib, and briakinumab. 
     Additional psoriasis agents for use in combination with the disclosed IL-17 antibodies, such as secukinumab, during treatment of psoriasis include apremilast, mometasome, voclosporin, ketokonazol, Neuroskin Forte, recombinant human interleukin-10, voclosporin, MK-3222, tofacitinib, VX-765, MED-I545, fluphenazine decanoate, acetomuinophn, bimosiamose cream, doxycycline, vancomycin, AbGn168, Vitamin D3, R05310074, fludarabine Calcipotriol and hydrocortisone (LEO 80190), LE80185 (Taclonex® Scalp topical suspension/Xamiol® gel), Focetria (Monovalent MF59-Adjuvanted vaccine, tgAAC94 gene therapy vector, Apremilast, Capsaicin, Psirelax, ABT-874 (anti IL-12), IDEC-114, MEDI-522, INCB018424 phosphate cream, LE29102, BMS 587101, CD 2027, CRx-191, 8-methoxypsoralen or 5- methoxypsoralen, Bicillin L-A, LY2525623, INCB018424, LY2439821, CEP-701, CC-10004, certolizumab (CZP), GW786034 (pazopanib), doxycycline Curcuminoids C3 Complex, NYC 0462, RG3421, hOKT3gamma1(Ala-Ala), BT061, teplizumab, Chondroitin sulphate, CNTO 1275, monoclonal antibody to IL-12p40 and IL-23 p40 subunits, BMS-582949, MK0873, MEDI-507, M518101, ABT-874, AMG 827, AN2728, AMG 714, AMG 139, PTH (1-34), U0267 Foam, CNTO 1275, QRX-101, CNTO 1959, LEO 22811, Imiquimod, CTLA4Ig, Alga Dunaliella Bardawil, AS101 Cream, pioglitazone, pimecrolimus, ranibizumab, Zidovudine CDP870 (Certolizumab pegol), Onercept (r-hTBP-1), ACT-128800, 4,4-dimethyl-benziso-2H-selenazine, CRx-191, CRx-197, doxercalciferol, LEO 19123 Cream (calcipotriol plus LEO 80122), LAS 41004, WBI-1001, tacrolimus, RAD001, rapamycin, rosiglitazone, pioglitazone, ABT-874, Aminopterin, AN2728, CD2027, ACT-128800, mometasone furoate, CT 327, clobetasol+LCD, BTT1023, E6201, topical vitamin B12, INCB018424 Phosphate Cream, Xamiol gel, IP10.C8, BFH772, LEO 22811, Fluphenazine, MM-093, Clobex, SCH 527123, CF101, SRT2104, BIRT2584, CC10004, Tetrathiomolybdate, CP-690,550, U0267, ASP015K, VB-201, Acitretin (also called U0279), RWJ-445380, Psoralait, Clobetasol propionate, botulinum toxin type A, alefacept, erlotinib, BCT194, Ultravate Ointment, Roflumilast, CNTO 1275, halobetasol, ILV-094, CTA018 cream, COL-121, MEDI-507, AEB071. Additional agents for use in combination with secukinumab during treatment of psoriasis include IL-6 antagonists, CD20 antagonistis, CTLA4 antagnonists, IL-17 antagonists, IL-8 antagnoists, IL-21 antagonistis, IL-22 antagonist, VGEF antagonists, CXCL antagonists, MMP antagonists, defensin antagonists, IL-1beta antagonists, and IL-23 antagonists (e.g., receptor decoys, antagonistic antibodies, etc.). A skilled artisan will be able to discern the appropriate dosages of the above agents for co-delivery with the disclosed IL-17 antibodies, such as secukinumab. 
     An IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof) is conveniently administered parenterally, e.g., intravenously (e.g., into the antecubital or other peripheral vein), intramuscularly, or subcutaneously. The duration of intravenous (IV) therapy using a pharmaceutical composition of the present disclosure will vary, depending on the severity of the disease being treated and the condition and personal response of each individual patient. Also contemplated is subcutaneous (SC) therapy using a pharmaceutical composition of the present disclosure. The health care provider will decide on the appropriate duration of IV or SC therapy and the timing of administration of the therapy, using the pharmaceutical composition of the present disclosure. 
     Preferred dosing and treatment regimens (including both induction and maintenance regimens) for treating new-onset plaque-type psoriasis and the other disorders found herein are provided in PCT Application No. PCT/US2011/064307 and PCT/IB2014/063902, which are incorporated by reference herein in their entirety. 
     The IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof) may be administered to the patient intravenously (IV), e.g., at about 10 mg/kg every other week during week 0, 2, and 4 and thereafter administered to the patient subcutaneously (SC), e.g., at about 75 mg-about 300 mg (e.g., about 150 mg, about 300 mg) monthly, beginning during week 8. In this manner, the patient may be dosed IV with about 10 mg/kg during week 0, 2, 4, and then the patient is dosed SC with about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) of the IL-17 antagonist (e.g., secukinumab) during week 8, 12, 16, 20, etc. 
     The IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof) may be administered to the patient SC, e.g., at about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) weekly during weeks 0, 1, 2, and 3, and thereafter administered to the patient SC, e.g., at about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) monthly, beginning during week 4. In this manner, the patient is dosed SC with about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) of the IL-17 antagonist (e.g., secukinumab) during weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, etc. 
     Alternatively, the IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof) may be administered to the patient without a loading regimen, e.g., the antagonist may be administered to the patient SC at about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) every 4 weeks (monthly). In this manner, the patient is dosed SC with about 150 mg-about 300 mg (e.g., ˜75 mg, ˜150 mg, ˜300 mg) of the IL-17 antagonist (e.g., secukinumab) during weeks 0, 4, 8, 12, 16, 20, etc. 
     It will be understood that dose escalation may be required for certain patients, e.g., patients that may display inadequate response to treatment with the IL-17 antagonists, e.g., IL-17 binding molecules (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecules (e.g., IL-17 receptor antibody or antigen-binding fragment thereof). Thus, SC dosages of secukinumab may be greater than about 150 mg to about 300 mg SC, e.g., about 80 mg, about 100 mg, about 125 mg, about 175 mg, about 200 mg, about 250 mg, about 350 mg, about 400 mg, about 450 mg, etc.; similarly, IV dosages may be greater than about 10 mg/kg, e.g., about 11 mg/kg, 12 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, etc. It will also be understood that dose reduction may also be required for certain patients, e.g., patients that display adverse events or an adverse response to treatment with the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab). Thus, dosages of the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab), may be less than about 150 mg to about 300 mg SC, e.g., about 80 mg, about 100 mg, about 125 mg, about 175 mg, about 200 mg, 250 mg, etc.; similarly, IV dosages may be less than about 10 mg/kg, e.g., about 9 mg/kg, 8 mg/kg, 5 mg/kg, 4 mg/kg, 3 mg/kg, 2 mg/kg, 1 mg/kg, etc. In some embodiments, the IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 receptor antibody or antigen-binding fragment thereof) may be administered to the patient at an initial dose of 150 mg or 300 mg delivered SC, and the dose is then escalated to about 450 mg if needed, as determined by a physician. 
     In some embodiment of the disclosed methods, uses and kits, after induction phase (typically the first 16 weeks of treatment, but may be extended until week 24 depending on the type of drug and dose regimen used) and during maintenance therapy, treatment can be continued unchanged if reduction in PASI is ≥75%. The treatment regimen can be modified (e.g., increased dose [e.g., from 150 mg to 300 mg, or from 300 mg to 400 mg or 450 mg] or frequency [e.g., from every 4 weeks to every 3 weeks or every 2 weeks]) if improvement of PASI is &lt;50%. In a situation where the therapeutic response improved ≥50% but &lt;75%, as assessed by PASI, therapy can be modified if the DLQI is &gt;5 but can be continued if the DLQI is ≤5. See Mrowietz et al. (2011) Arch Dermatol Res. 303(1):1-10. 
     The timing of dosing is generally measured from the day of the first dose of secukinumab (which is also known as “baseline”). However, health care providers often use different naming conventions to identify dosing schedules, as shown in Table 2. 
     
       
         
           
               
             
               
                 TABLE 2 
               
               
                   
               
               
                 Common naming conventions for dosing regimens. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Week 
                   0 /1 
                   1 /2 
                   2 /3 
                   3 /4 
                   4 /5 
                   5 /6 
                   6 /7 
                   7 /8 
                   8 /9 
                   9 /10 
                   10 /11 
                 etc  
               
               
                 1 st  day 
                 0/ 1   
                 7/ 8   
                 14/ 15   
                 21/ 22   
                 28/ 29   
                 35/ 36   
                 42/ 43   
                 49/ 50   
                 56/ 57   
                 63/ 64   
                 70/ 71   
                 etc. 
               
               
                 of week 
               
               
                   
               
               
                 Bolded items refer to the naming convention used herein. 
               
            
           
         
       
     
     Notably, week zero may be referred to as week one by some health care providers, while day zero may be referred to as day one by some health care providers. Thus, it is possible that different physicians will designate, e.g., a dose as being given during week 3/on day 21, during week 3/on day 22, during week 4/on day 21, during week 4/on day 22, while referring to the same dosing schedule. For consistency, the first week of dosing will be referred to herein as week 0, while the first day of dosing will be referred to as day 1. However, it will be understood by a skilled artisan that this naming convention is simply used for consistency and should not be construed as limiting, i.e., weekly dosing is the provision of a weekly dose of the IL-17 antibody regardless of whether the physician refers to a particular week as “week 1” or “week 2”. Moreover, in a preferred dosing regimen, the antibody is administered during week 0, 1, 2, 3, 4 8, 12, 16, 20, etc. Some providers may refer to this regimen as weekly for five weeks and then monthly (or every 4 weeks) thereafter, beginning during week 8, while others may refer to this regimen as weekly for four weeks and then monthly (or every 4 weeks) thereafter, beginning during week 4. Thus, it will be appreciated by a skilled artisan that administering a patient an injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4 is the same as: 1) administering the patient an injection at weeks 0, 1, 2, 3, and 4, followed by once monthly dosing starting at week 8; 2) administering the patient an injection at weeks 0, 1, 2, 3 and 4 followed by dosing every 4 weeks; and 3) administering the patient an injection at weeks 0, 1, 2, 3 and 4 followed by monthly administration. 
     Disclosed herein are methods of, and IL-17 antagonists for use in, treating a patient having new-onset plaque-type psoriasis, comprising administering an IL-17 antibody or antigen-binding fragment thereof to a patient in need thereof, wherein the IL-17 antibody or antigen-binding fragment thereof binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are methods of, and IL-17 antagonists for use in, modulating the immune mechanisms causing psoriasis disease chronicity in a new-onset plaque-type psoriasis, wherein the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a KD of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are methods of, and IL-17 antagonists for use in, decreasing the number of tissue resident memory T-cells in the skin of a patient having new-onset plaque-type psoriasis, decreasing the number of subset effector T-cells producing interleukin-17 (IL-17) and/or interleukin-22 (IL-22) in the skin of a patient having new-onset plaque-type psoriasis, decreasing the number of regulatory T-cells in the skin of a patient having new-onset plaque-type psoriasis, and/or decreasing the number of dermal dendritic cell-Tcell aggregates in the skin of a patient having new-onset plaque-type psoriasis, slowing psoriasis disease progression in a patient having new-onset plaque-type psoriasis, decreasing the severity of psoriasis flares in a patient having new-onset plaque-type psoriasis, decreasing the frequency of psoriasis flares in a patient having new-onset plaque-type psoriasis, and/or preventing psoriasis flares in a patient having new-onset plaque-type psoriasis, comprising administering an IL-17 antibody or antigen-binding fragment thereof to a patient in need thereof, wherein the IL-17 antibody or antigen-binding fragment thereof binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are IL-17 antagonists (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) for use in the manufacture of a medicament for treating a patient having new-onset plaque-type psoriasis, wherein the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are IL-17 antagonists (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) for use in the manufacture of a medicament for modulating the immune mechanisms causing psoriasis disease chronicity in a new-onset plaque-type psoriasis patient, wherein the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are IL-17 antagonists (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) for use in the manufacture of a medicament for treating a patient having new-onset plaque-type psoriasis, wherein the medicament is formulated to comprise containers, each container having a sufficient amount of the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) to allow subcutaneous delivery of at least about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) of the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) per unit dose, and further wherein the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     Additionally disclosed herein are IL-17 antagonists (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) for use in the manufacture of a medicament for modulating the immune mechanisms causing psoriasis disease chronicity in a new-onset plaque-type psoriasis patient, wherein the medicament is formulated to comprise containers, each container having a sufficient amount of the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) to allow subcutaneous delivery of at least about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) per unit dose, and further wherein the IL-17 antagonist (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody or antigen-binding fragment thereof has a K D  of about 100-200 pM, and wherein the IL-17 antibody or antigen-binding fragment thereof has an in vivo half-life of about 4 weeks. 
     As used herein, the phrase “formulated at a dosage to allow [route of administration] delivery of [a designated dose]” is used to mean that a given pharmaceutical composition can be used to provide a desired dose of an IL-17 antagonist, e.g., an IL-17 antibody, e.g., secukinumab, via a designated route of administration (e.g., SC or IV). As an example, if a desired subcutaneous dose is 300 mg, then a clinician may use 2 ml of an IL-17 antibody formulation having a concentration of 150 mg/ml, 1 ml of an IL-17 antibody formulation having a concentration of 300 mg/ml, 0.5 ml of an IL-17 antibody formulation having a concentration of 600 mg/ml, etc. In each such case, these IL-17 antibody formulations are at a concentration high enough to allow subcutaneous delivery of the IL-17 antibody. Subcutaneous delivery typically requires delivery of volumes of less than or equal to about 2 ml, preferably a volume of about 1 ml or less. Preferred formulations are liquid pharmaceutical compositions comprising about 25 mg/mL to about 150 mg/mL secukinumab, about 10 mM to about 30 mM histidine pH 5.8, about 200 mM to about 225 mM trehalose, about 0.02% polysorbate 80, and about 2.5 mM to about 20 mM methionine. 
     As used herein, the phrase “container having a sufficient amount of the IL-17 antagonist to allow delivery of [a designated dose]” is used to mean that a given container (e.g., vial, pen, syringe) has disposed therein a volume of an IL-17 antagonist (e.g., as part of a pharmaceutical composition) that can be used to provide a desired dose. As an example, if a desired dose is 150 mg, then a clinician may use 2 ml from a container that contains an IL-17 antibody formulation with a concentration of 75 mg/ml, 1 ml from a container that contains an IL-17 antibody formulation with a concentration of 150 mg/ml, 0.5 ml from a container contains an IL-17 antibody formulation with a concentration of 300 mg/ml, etc. In each such case, these containers have a sufficient amount of the IL-17 antagonist to allow delivery of the desired 150 mg dose. 
     Additionally disclosed herein are methods of, and IL-17 antagonists for use in, decreasing the likelihood that a new-onset psoriasis patient will develop psoriatic arthritis, delaying the onset of psoriatic arthritis in a new-onset psoriasis patient, and preventing progression from psoriasis to psoriatic arthritis in a new-onset psoriasis patient, comprising administering the patient a dose of about 150 mg-about 300 mg (e.g., 150 mg or 300 mg) of an IL-17 antibody or antigen-binding fragment thereof by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by once monthly dosing. 
     In some embodiments of the disclosed uses, methods, and kits, the patient has mild plaque-type psoriasis. In some embodiments of the disclosed uses, methods, and kits, the patient has moderate to severe plaque-type psoriasis. In some embodiments of the disclosed uses, methods, and kits, the patient has not been previously treated with a systemic treatment for psoriasis. In some embodiments of the disclosed uses, methods, and kits, the patient is biological-naive. In some embodiments of the disclosed uses, methods, and kits, the patient is topical-naive. In some embodiments of the disclosed uses, methods, and kits, the patient has not been previously treated with phototherapy for psoriasis. 
     In some embodiments of the disclosed uses, methods, and kits, the patient is administered about 150 mg-about 300 mg of the IL-17 antibody or antigen-binding fragment thereof by subcutaneous (SC) injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4. In some embodiments of the disclosed uses, methods, and kits, the patient is administered about 150 mg of the IL-17 antibody or antigen-binding fragment thereof by SC injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4. In some embodiments of the disclosed uses, methods, and kits, the patient is administered about 300 mg of the IL-17 antibody or antigen-binding fragment thereof by SC injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4. 
     In some embodiments, the step of administering the IL-17 antibody every four weeks provides an average steady-state trough level of the IL-17 antibody between about 5 μg/ml-about 70 μg/ml, about 5 μg/ml-about 33 μg/ml, or about 11 μg/ml-about 70 μg/ml. 
     In some embodiments of the disclosed uses, methods, and kits, the IL-17 antibody or antigen-binding fragment thereof comprises: i) an immunoglobulin heavy chain variable domain (V H ) comprising the amino acid sequence set forth as SEQ ID NO: 8; ii) an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence set forth as SEQ ID NO:10; iii) an immunoglobulin V H  domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V L  domain comprising the amino acid sequence set forth as SEQ ID NO:10; iv) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; v) an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO: 5 and SEQ ID NO:6; vi) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13; vii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; viii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; ix) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14; x) an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or xi) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15. 
     In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is a monoclonal antibody. In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is a human or humanized antibody. In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is a human antibody. In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is a human antibody of the IgG 1  subtype. In some embodiments the IL-17 antibody or antigen-binding fragment thereof has a kappa light chain. In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is a human antibody of the IgG 1  kappa type. In some embodiments of the disclosure, the IL-17 antibody or antigen-binding fragment thereof is secukinumab. 
     In some embodiments, the dose of the IL-17 antibody or antigen-binding fragment thereof is about 300 mg if the patient weighs &gt; or ≥90 kg. In some embodiments, the dose of the IL-17 antibody or antigen-binding fragment thereof is about 300 mg if the patient weighs &gt; or ≥ 100 kg. In some embodiments, the dose of the IL-17 antibody or antigen-binding fragment thereof is about 150 mg if the patient weighs &lt; or ≤90 kg. In some embodiments, the dose of the IL-17 antibody or antigen-binding fragment thereof is about 150 mg if the patient weighs &lt; or ≤ 100 kg. 
     In some embodiments, the dose of the IL-17 antibody (e.g., secukinumab) is about 150 mg, the IL-17 antibody (e.g., secukinumab) is comprised in a liquid pharmaceutical formulation, 1 ml of the pharmaceutical formulation is disposed within a pre-filled syringe, injection pen, or autoinjector, which is disposed within a kit, wherein the kit further comprises instructions for use. In some embodiments, the dose of the IL-17 antibody (e.g., secukinumab) is about 150 mg, the IL-17 antibody (e.g., secukinumab) is comprised in a liquid pharmaceutical formulation at a concentration of 150 mg/ml, 1 ml of the pharmaceutical formulation is disposed within an autoinjector, which is disposed within a kit, wherein the kit further comprises instructions for use. 
     In some embodiments, the dose of the IL-17 antibody (e.g., secukinumab) is about 300 mg, the IL-17 antibody (e.g., secukinumab) is comprised in a liquid pharmaceutical formulation at a concentration of 150 mg/ml, the pharmaceutical formulation is disposed within pre-filled syringes, injection pens, or autoinjectors, which are disposed within a kit, wherein the kit further comprises instructions for use. In some embodiments, the dose of the IL-17 antibody is about 300 mg, the IL-17 antibody (e.g., secukinumab) is comprised in a liquid pharmaceutical formulation at a concentration of 150 mg/ml, 2 ml of the pharmaceutical formulation is disposed within an autoinjector, which is disposed within a kit, wherein the kit further comprises instructions for use. 
     In some embodiments, the patient has a baseline IGA score of ≥3. In some embodiments the patient has a baseline PASI score of ≥12. In some embodiments, the patient has a baseline BSA of ≥10%. Patients&#39; PASI and IGA scores in response to treatment with secukinumab may be found in Langley et al. (2014) N Engl J Med 371:326-38, which is incorporated by reference herein in its entirety. 
     In some embodiments of the disclosed uses, methods, and kits, at least 60%, at least 67%, at least 70%, at least 71%, at least 77%, or at least 81% of patients (e.g., adult patients) treated according to the disclosed methods achieve PASI 75 at week 12. 
     In some embodiments, at least 50%, at least 51%, at least 62%, or at least 65% of patients (e.g., adult patients) patients treated according to the disclosed methods a response of 0 or 1 on the modified investigator&#39;s global assessment (IGA) at week 12. 
     In some embodiments of the disclosed uses, methods, and kits, at least 35%, at least 39%, at least 41%, at least 54%, or at least 59% of patients (e.g., adult patients) treated according to the disclosed methods achieve PASI 90 at week 12. 
     In some embodiments, at least 10%, at least 12%, at least 14%, at least 24%, or at least 28% of patients (e.g., adult patients) treated according to the disclosed methods achieve PASI 100 at week 12. 
     In some embodiments, the disclosed methods are used to treat a population of patients having moderate to severe chronic plaque psoriasis, and at least 60%, at least 67%, at least 70%, at least 71%, at least 77%, or at least 81% of said patients achieve at least PASI 75 response at week 12 of the treatment. 
     In some embodiments, the disclosed methods are used to treat a population of patients having moderate to severe chronic plaque psoriasis, and at least 50%, at least 51%, at least 62%, or at least 65% of said patients achieve a response of 0 or 1 on the modified investigator&#39;s global assessment (IGA) at week 12 of the treatment. 
     In some embodiments, the disclosed methods are used to treat a population of patients having moderate to severe chronic plaque psoriasis, and at least 35%, at least 39%, at least 41%, at least 54%, or at least 59% of said patients achieve at least PASI 90 response at week 12 of the treatment. 
     In some embodiments, the disclosed methods are used to treat a population of patients having moderate to severe chronic plaque psoriasis, and at least 10%, at least 12%, at least 14%, at least 24%, or at least 28% of said patients achieve PASI 100 response at week 12 of the treatment. Additionally disclosed herein are methods of treating a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering the patient about 150 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4, wherein the patient is biological-naïve. Additionally disclosed herein are methods of treating a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering the patient about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4, wherein the patient is biological-naïve. 
     Additionally disclosed herein are methods of treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having early-onset moderate to severe chronic plaque psoriasis 150 mg or 300 mg of secukinumab during week 0, 1, 2, 3, and 4, and then monthly thereafter, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 60%, at least 67%, at least 70%, at least 71%, at least 77%, or at least 81%, of said patients achieve at least PASI 75 response at week 12 of the treatment. Preferably, the patient is biological-naïve. 
     Additionally disclosed herein are methods of treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having early-onset moderate to severe chronic plaque psoriasis 150 mg or 300 mg of secukinumab during week 0, 1, 2, 3, and 4, and then monthly thereafter, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 50%, at least 51%, at least 62%, or at least 65% of said patients achieve a response of 0 or 1 on the modified investigator&#39;s global assessment (IGA) at week 12 of the treatment. Preferably, the patient is biological-naïve. 
     Additionally disclosed herein are methods of treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having early-onset moderate to severe chronic plaque psoriasis 150 mg or 300 mg of secukinumab during week 0, 1, 2, 3, and 4, and then monthly thereafter, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 35%, at least 39%, at least 41%, at least 54%, or at least 59% of said patients achieve at least PASI 90 response at week 12 of the treatment. Preferably, the patient is biological-naïve. 
     Additionally disclosed herein are methods of treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having early-onset moderate to severe chronic plaque psoriasis 150 mg or 300 mg of secukinumab during week 0, 1, 2, 3, and 4, and then monthly thereafter, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 10%, at least 12%, at least 14%, at least 24%, or at least 28% of said patients achieve PASI 100 response at week 12 of the treatment. Preferably, the patient is biological-naïve. 
     Additionally disclosed herein are methods of modulating the immune mechanisms causing psoriasis disease chronicity in a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering the patient about 150 mg or about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4, wherein the patient is biological-naïve, wherein the patient is biological-naïve. Additionally disclosed herein are methods of reducing the number of tissue resident memory cells in the lesional skin of a patient having moderate to severe new-onset plaque-type psoriasis, comprising administering the patient about 150 mg or about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4, wherein the patient is biological-naïve. 
     Additionally disclosed herein are methods of, and IL-17 antagonists for use in, decreasing the likelihood that a new-onset psoriasis patient will develop psoriatic arthritis, delaying the onset of psoriatic arthritis in a new-onset psoriasis patient, and preventing progression from psoriasis to psoriatic arthritis in a new-onset psoriasis patient, comprising administering the patient a dose of about 150 mg-about 300 mg of an IL-17 antibody or antigen-binding fragment thereof by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by once monthly dosing. 
     Additionally disclosed herein are methods of treating pyoderma gangrenosum, ichthyoses, rosacea (e.g, papulopustular rosacea), pytiriasis  rubra  pilaris, lichen planopilaris, atopic dermatitis, allergic contact dermatitis, alopecia areata, or human papilloma virus (HPV), comprising administering the patient about 150 mg or about 300 mg of secukinumab by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by once monthly dosing. Additionally disclosed herein are methods of treating pyoderma gangrenosum, ichthyoses, rosacea (e.g., papulopustular rosacea), lichen planopilaris, pytiriasis rubra pilaris, atopic dermatitis, allergic contact dermatitis, alopecia areata, or human papilloma virus (HPV), comprising administering the patient about 150 mg or about 300 mg of secukinumab by subcutaneous injection every four weeks (monthly). 
     Kits 
     The disclosure also encompasses kits for treating new-onset plaque-type psoriasis. Such kits comprise an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen-binding fragment thereof) (e.g., in liquid or lyophilized form) or a pharmaceutical composition comprising the IL-17 antagonist (described supra). Additionally, such kits may comprise means for administering the IL-17 antagonist (e.g., an autoinjector, a syringe and vial, a prefilled syringe, a prefilled pen) and instructions for use. These kits may contain additional therapeutic psoriasis agents (described supra) for treating new-onset plaque-type psoriasis, e.g., for delivery in combination with the enclosed IL-17 antagonist, e.g., IL-17 binding molecule, e.g., IL-17 antibody, e.g., secukinumab. Such kits may also comprise instructions for administration of the IL-17 antagonist (e.g., IL-17 antibody, e.g., secukinumab) to treat the new-onset plaque-type psoriasis patient. Such instructions may provide the dose (e.g., 10 mg/kg, 75 mg, 150 mg, 300 mg), route of administration (e.g., IV, SC), and dosing regimen (e.g., every other week during weeks 0, 2, and 4, and thereafter monthly, beginning during week 8; weekly during week 0, 1, 2, and 3 and thereafter monthly (every 4 weeks), beginning during week 4; etc.) for use with the enclosed IL-17 antagonist, e.g., IL-17 binding molecule, e.g., IL-17 antibody, e.g., secukinumab. 
     The phrase “means for administering” is used to indicate any available implement for systemically administering a drug to a patient, including, but not limited to, a pre-filled syringe, a vial and syringe, an injection pen, an autoinjector, an IV drip and bag, a pump, etc. With such items, a patient may self-administer the drug (i.e., administer the drug without the assistance of a physician) or a medical practitioner may administer the drug. 
     Disclosed herein are kits for use in modulating the immune mechanisms causing psoriasis disease chronicity in a new-onset plaque-type psoriasis patient, and/or treating a patient having new-onset plaque-type psoriasis, comprising an IL-17 antagonist (e.g., IL-17 binding molecule, e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab). In some embodiments, the kit further comprises means for administering the IL-17 antagonist to the patient. In some embodiments, the kit further comprises instructions for administration of the IL-17 antagonist, wherein the instructions indicate that the IL-17 antagonist (e.g., IL-17 binding molecule, e.g., IL-17 antibody or antigen-binding fragment thereof, e.g., secukinumab) is to be administered to the patient SC at about 150 mg-about 300 mg (e.g., about 150 mg, or about 300 mg) weekly during weeks 0, 1, 2, and 3, and thereafter SC at about 150 mg-about 300 mg (e.g., about 150 mg, about 300 mg) monthly (every 4 weeks), beginning during week 4. In some embodiments, the instructions will provide for dose escalation (e.g., from a dose of about 150 mg or about 300 mg to a higher dose of about 450 mg as needed, to be determined by a physician). 
     General 
     In preferred embodiments of the disclosed methods, treatments, medicaments, regimens, uses and kits, the IL-17 antagonist is an IL-17 binding molecule. In preferred embodiments, the IL-17 binding molecule is an IL-17 antibody or antigen-binding fragment thereof. In some embodiments of the disclosed methods, treatments, regimens, uses and kits, the IL-17 antibody or antigen-binding fragment thereof is selected from the group consisting of: a) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of human IL-17 comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129; b) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of human IL-17 comprising Tyr43, Tyr44, Arg46, Ala79, Asp80; c) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain; d) an IL-17 antibody or antigen-binding fragment thereof that binds to an epitope of an IL-17 homodimer having two mature human IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 binding molecule has a K D  of about 100-200 pM, and wherein the IL-17 binding molecule has an in vivo half-life of about 23 to about 35 days; and e) an IL-17 antibody or antigen-binding fragment thereof comprising: i) an immunoglobulin heavy chain variable domain (V H ) comprising the amino acid sequence set forth as SEQ ID NO: 8; ii) an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence set forth as SEQ ID NO:10; iii) an immunoglobulin V H  domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V L  domain comprising the amino acid sequence set forth as SEQ ID NO:10; iv) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; v) an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; vi) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13; vii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; viii) an immunoglobulin V H  domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V L  domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; ix) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14; x) an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or xi) an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15. 
     In some embodiments of the disclosed methods, kits, or uses, the IL-17 antibody or antigen-binding fragment thereof is a monoclonal antibody. In some embodiments of the disclosed methods, kits, or uses the IL-17 antibody or antigen-binding fragment thereof is a human or humanized antibody, preferably a human antibody. In some embodiments of the disclosed methods, kits, or uses, the IL-17 antibody or antigen-binding fragment thereof is a human antibody of the IgG 1  isotype. In some embodiments of the disclosed methods, kits, or uses, the antibody or antigen-binding fragment thereof is secukinumab. 
     The details of one or more embodiments of the disclosure are set forth in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated by reference. The following Examples are presented in order to more fully illustrate the preferred embodiments of the disclosure. These examples should in no way be construed as limiting the scope of the disclosed patient matter, as defined by the appended claims. 
     EXAMPLES 
     Example 1: Imiquimod Skin and Ear Inflammation 
     Imiquimod is used for the topical treatment of genital and perineal warts caused by the human papilloma virus. The clinical indications for this therapy have further been expanded to include treatment of other virus-associated skin abnormalities as well as pre-cancerous and cancerous skin lesions such as actinic keratoses and superficial basal cell carcinomas. Clinically, it was found that imiquimod can exacerbate psoriasis in patients whose disease was previously well-controlled during topical treatment of actinic keratoses and superficial basal cell carcinomas. Imiquimod induced exacerbation of psoriasis occurs at both the treated area and, interestingly, also at distant skin sites that were previously unaffected by the disease. Thus, treatment of mice with imiquimod cream, which produces skin lesions similar to psoriasis, can be used to investigate putative anti-psoriasis therapies at an early stage of the disease process. (van der Fits et al. (2009) J. Immunol 182:5836-5845). 
     A. Systemic Delivery 
     Female Balb/c mice (8-10 weeks old) were used for the skin inflammation model. Cream containing 5% imiquimod or vehicle cream was applied daily to the shaved backs of the mice (total imiquimod dose, 12.5 mg per mouse). The skin thickness on the back was measured daily using digital callipers. 
     Anti-IL-17 Ab was administered, by intraperitoneal injection, on days −3, 0, 4, 7 and 11 relative to the first application of the cream. The skin thickness was calculated as % change vs day 0 (baseline) for each time point to give Area Under the Curve (AUC) graphs for vehicle cream, imiquimod cream and Ab treatment groups. The percentage inhibitions of the individual animals in each treatment group AUCs were calculated vs. the imiquimod group AUC (0% inhibition) using an Excel spreadsheet. 
     As shown in  FIG. 1 , treatment with anti-IL-17 Ab, dosed at 100 mg/kg i.p. on days −3, 0, 4, 7 and 11, inhibited skin swelling AUC [0-14 days]  by 22.94±12.25%. Thus, early systemic treatment of imiquimod-induced skin thickness with an IL-17 antibody reduces skin thickness in this model. 
     B. Local Delivery 
     Female Balb/c mice (8-10 weeks old) were used for the ear inflammation model. Cream containing 5% imiquimod was applied daily to both ears of the mice (total imiquimod dose, 12.5 mg per mouse). The ear thickness of both ears was measured daily using digital callipers and averaged. 
     Anti-IL-17 Ab was administered, as a single dose by subcutaneous injection at 100 mg/kg, on day −3 relative to the first application of the cream. The ear thickness was calculated as change vs. day 0 (baseline) for each time point to give Area Under the Curve (AUC) graphs for imiquimod cream and Ab treatment groups. The AUC percentage inhibitions of the individual animals in each treatment group were calculated vs the imiquimod group AUC (0% inhibition) using an Excel spreadsheet. 
     As shown in  FIG. 2 , treatment with anti-IL-17 Ab, dosed at 100 mg/kg s.c. on day −3 only, inhibited the ear swelling AUC [0-10 days]  by 25.50±2.28%. *p&lt;0.05, unpaired t-test. Thus, early local treatment of imiquimod-induced ear thickness with an IL-17 antibody reduces ear thickness in this model. 
     Together, the data from the imiquimod model studies suggest that early treatment of new-onset psoriasis with an IL-17 antibody (delivered locally or systemically) may reduce the inflammation (e.g., thickness and/or swelling) associated with the plaque-type skin lesions occurring during psoriasis. 
     Example 2: IL-23-Induced Ear Swelling 
     It has been proposed that IL-23, a cytokine driving the development of IL-17- and IL-22-producing Th17 cells, is functionally involved in the pathogenesis of psoriasis. (See, e.g., van der Fits et al. (2009) J. Immunol 182:5836-5845). Expression of IL-23 is increased in psoriatic skin lesions, and increased numbers of Th17 cells are present. Intradermal injection of IL-23 into mouse skin results in erythema, a mixed inflammatory infiltrate and epidermal hyperplasia, as well as swelling at the injection site after repeated injections. Since both IL-23 and IL-17 have been found to be critical in the development of psoriasis, the IL-23 ear injection model in mice can also be used as a simple and rapid method to investigate therapies which may be useful in the treatment of early psoriasis. 
     Female Balb/c mice (˜20 g) were injected i.d. in the right ear pinna with 1 μg of IL-23 in 10 μl PBS and with 10 μl of PBS alone into the left ear pinna (control ear) on day 0. The ear injections with IL-23 and PBS were repeated on days 2, 5 and 7. Ear thickness was measured using digital callipers, on days 0, 5, 7 and 8. 
     Anti-IL-17 Ab or isotype control Ab treatment was given at 30 mg/kg i.p. as a single dose one day prior to the first ear injections on day 0. Right ear swelling was calculated as a ratio of left ear swelling, and the R/L, ear swelling ratio plotted against time to give Area Under the Curve (AUC) graphs for control and treatment groups. The AUC percentage inhibitions of the individual animals in each treatment group were calculated vs. the control group AUC (0% inhibition) using an Excel spreadsheet. 
     As shown in  FIG. 3 , treatment with anti-IL-17 Ab, dosed at 30 mg/kg i.p. on day −1 only, inhibited the ear swelling AUC[0-8 days] by 38.57±3.98%. ***p&lt;0.001, paired t-test. This suggests that early treatment of new-onset psoriasis with an IL-17 antibody may reduce the inflammation (e.g., swelling) associated with the plaque-type skin lesions occurring during psoriasis. 
     Example 3: Analysis of the Psoriasis Patients&#39; Responses to Treatment with Secukinumab by Disease Duration 
     Details of the design and results of two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; CAIN457A2302) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; CAIN457A2303) are presented in Langley et al. (2014) N Engl J Med 371:326-38. The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, PASI 75 rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P&lt;0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator&#39;s global assessment (IGA) at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P&lt;0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. 
     The ERASURE and FIXTURE data was reanalyzed to determine whether the effect of secukinumab 150 mg and 300 mg on PASI 75, 90 and 100 and IGA0/1 response rates was different for subgroups of patients at different stages in their psoriasis disease career. The following three subgroups were analyzed: subjects at time of trial enrollment that had been diagnosed with moderate to severe psoriasis for ≤2 years, 2-≤10 years and ≥10 years. A summary of time since first diagnosis of psoriasis (years) for the patients in ERASURE and FIXTURE is given below in Table 3: 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Disease history and baseline disease characteristics of the induction 
               
               
                 treatment group (safety set).  
               
            
           
           
               
               
               
               
            
               
                 Background 
                 AIN457 150 mg 
                 AIN457 300 mg 
                 Placebo 
               
               
                 Characteristics 
                 N = 692 
                 N = 690 
                 N = 694 
               
               
                   
               
            
           
           
               
            
               
                 Time since first diagnosis of psoriasis (years) 
               
            
           
           
               
               
               
               
            
               
                 n 
                 692 
                 690 
                 694 
               
               
                 Mean 
                 17.948 
                 17.025 
                 17.490 
               
               
                 
                   
                 
                 12.4643 
                 12.0243 
                 12.2314 
               
               
                 Minimum 
                 0.51 
                 0.49 
                 0.51 
               
               
                 Q2 
                 8.555 
                 7.826 
                 7.844 
               
               
                 Median 
                 15.413 
                 14.676 
                 18.069 
               
               
                 Q3 
                 25.021 
                 23.299 
                 28.205 
               
               
                 Maximum 
                 69.01 
                 61.48 
                 68.13 
               
               
                   
               
               
                     indicates data missing or illegible when filed 
               
            
           
         
       
     
     As shown in  FIG. 5 , at week 52, for secukinumab 150 mg treatment, except PASI 100, the percentage of response is highest in the short-term subgroup (i.e., patients who had been diagnosed with psoriasis for ≤2 years prior to treatment). This was consistently followed by the mid-term patient subgroup (i.e., patients who had been diagnosed with psoriasis for 2-≤10 years) and the long-term patient subgroup (i.e., patients who had been diagnosed with psoriasis for ≥10 years). Thus, following treatment with 150 mg secukinumab, there is a greater rate of responders amongst short-term patients in achieving PASI 75/90 and IGA 0/1 improvements compared to patients with more advanced disease. Of those patients having psoriasis duration for ≤2 years prior to treatment (n=30), 14 had previously been treated with non-biological systemic therapy; all patients were biological-naïve and topical naive. Further analysis showed that of patients having psoriasis duration for ≤1 years prior to treatment (n=7), 2 had previously been treated with non-biological systemic therapy; all patients were biological-naive and topical naive. 
     As shown in  FIG. 6 , at week 52, for secukinumab 300 mg treatment, for PASI 75 and PASI 100, the difference between the rate of responders in short-term (≤2 yr) versus not-short-term (&gt;2 yr) is only about 1.1%. However, for PASI 90 and IGA 0/1, the percent of responders in the short-term subgroup is higher than in the mid- and long-term subgroups. Thus, following treatment with 300 mg secukinumab, there is a greater rate of responders amongst short-term patients in achieving PASI 90 and IGA 0/1 improvements compared to patients with more advanced disease. Of those patients having psoriasis duration for ≤2 years prior to treatment (n=33), 22 had previously been treated with non-biological systemic therapy; all patients were biological-naive and topical naive. Further analysis showed that of patients having psoriasis duration for ≤1 years prior to treatment (n=11), 8 had previously been treated with non-biological systemic therapy; all patients were biological-naïve and topical naïve. 
     A similar analysis was performed for patients in study CAIN457A2317, which used 300 mg secukinumab to treat moderate to severe psoriasis. Interestingly, in this analysis, the rate of improvement achieved by the short-term subgroup was comparable to the rate observed in patients with more advanced disease (data not shown). However, it must be noted that in CAIN457A2317 there were only 15 patients having psoriasis duration for ≤2 years prior to treatment, making comparisons between the subgroups difficult for this trial. Of those patients having psoriasis duration for ≤2 years prior to treatment (n=15), 8 had previously been treated with non-biological systemic therapy, and one had previously been treated with biological systemic therapy. Further analysis showed that of patients having psoriasis duration for ≤1 years prior to treatment (n=5), 4 had previously been treated with non-biological systemic therapy; all patients were biological-naïve. 
     Example 4: CAIN457A2322—A Randomized, Multicenter Study to Evaluate the Effect of Secukinumab Administered to Patients Suffering from New-Onset Moderate to Severe Plaque Psoriasis 
       
     
       
         
           
               
               
             
               
                   
               
               
                 Protocol number  
                 CAIN457A2322 
               
               
                   
               
             
            
               
                 Title  
                 A randomized, multicenter STudy to evaluate the  
               
               
                   
                 Effect of secukinumab 300 mg s.c. administered  
               
               
                   
                 during 52 weeks to patients suffering from  
               
               
                   
                 new-onset moderate to severe plaque Psoriasis as  
               
               
                   
                 early Intervention compared to standard  
               
               
                   
                 treatment with narrow-band UVB (STEPIn  
               
               
                   
                 study) 
               
               
                 Brief title  
                 Study of the efficacy of early intervention with  
               
               
                   
                 secukinumab 300 mg s.c. compared to narrow- 
               
               
                   
                 band UVB in patients with new-onset moderate  
               
               
                   
                 to severe plaque psoriasis  
               
               
                 Sponsor and clinical  
                 Novartis  
               
               
                 phase  
                 Phase IV  
               
               
                 Investigation type  
                 Drug  
               
               
                 Study type  
                 Interventional  
               
               
                 Purpose and rationale  
                 The purpose of this study is to determine whether 
               
               
                   
                 early intervention with subcutaneous (s.c.)  
               
               
                   
                 secukinumab 300 mg in patients with new-onset  
               
               
                   
                 moderate to severe plaque psoriasis may lead to  
               
               
                   
                 prolonged symptom-free periods by preventing  
               
               
                   
                 reactivation of old lesions or ultimately totally  
               
               
                   
                 hindering the occurrence of new lesions, i.e.,  
               
               
                   
                 changing the natural course of the disease (Main  
               
               
                   
                 Study).  
               
               
                 Primary objective  
                 To demonstrate that early treatment with  
               
               
                   
                 secukinumab 300 mg s.c. (Arm A1) is superior  
               
               
                   
                 to standard of care treatment with nb-UVB (Arm  
               
               
                   
                 B1) in patients with new-onset moderate to  
               
               
                   
                 severe plaque psoriasis with respect to patients  
               
               
                   
                 achieving ≥90% improvement (reduction) in  
               
               
                   
                 psoriasis area and severity index (PASI 90)  
               
               
                   
                 response at Week 52.  
               
               
                 Secondary objectives  
                 Key secondary objective  
               
               
                   
                 To evaluate the superiority of early treatment  
               
               
                   
                 with secukinumab (Arm A1) versus nb-UVB  
               
               
                   
                 (Arm B1) based on the proportion of all  
               
               
                   
                 randomized patients who achieve at least PASI  
               
               
                   
                 90 at Week 104.  
               
               
                   
                 Additional secondary objective  
               
               
                   
                 To evaluate the effects of early treatment with  
               
               
                   
                 secukinumab (Arm A1) compared with nb-UVB  
               
               
                   
                 (Arm B1) based on the proportion of all  
               
               
                   
                 randomized patients who achieve at least  
               
               
                   
                 investigator&#39;s global assessment (IGA mod 2011)  
               
               
                   
                 of 0 or 1 at Week 52 and at Week 104.  
               
               
                 Study design  
                 The design consists of the Main Study involving  
               
               
                   
                 all patients in Arms A1 (A1a and A1b) and B1  
               
               
                   
                 (B1a and B1b) and a Mechanistic Sub-study,  
               
               
                   
                 which comprises 5 treatment arms (A1b, A2,  
               
               
                   
                 B1b, C1, and C2). 
               
               
                   
                 The Main Study will be multicenter, randomized,  
               
               
                   
                 2-treatment-arm (secukinumab and nb-UVB),  
               
               
                   
                 parallel-group and open-label.  
               
               
                 Population  
                 The overall study population (Main Study and  
               
               
                   
                 Mechanistic Sub-study) will consist of a total of  
               
               
                   
                 196 male and female patients aged between 18  
               
               
                   
                 and 50 years inclusive.  
               
               
                   
                 Main Study  
               
               
                   
                 The Main Study will be conducted in patients  
               
               
                   
                 with new-onset moderate to severe plaque  
               
               
                   
                 psoriasis not previously treated with any  
               
               
                   
                 systemic treatment or phototherapy.  
               
               
                   
                 A total of 160 patients will be randomized to  
               
               
                   
                 Arm A1 or Arm B1 in approximately 75 sites  
               
               
                   
                 worldwide. Since a maximum screening failure  
               
               
                   
                 rate of 20% is expected, approximately 245  
               
               
                   
                 patients will be screened.  
               
               
                   
                 Mechanistic Sub-study  
               
               
                   
                 Any patient who consents can participate in the  
               
               
                   
                 Mechanistic Sub-study. Patients with new-onset  
               
               
                   
                 plaque psoriasis will be randomized to Arm A1b,  
               
               
                   
                 Arm A2, or Arm B1b, those with chronic plaque  
               
               
                   
                 psoriasis will be randomized to Arm C1 and Arm  
               
               
                   
                 C2 (12 patients each). For Arm A1b or Arm B1b,  
               
               
                   
                 the first 12 patients will be included on a first  
               
               
                   
                 come first serve basis.  
               
               
                 Key inclusion criteria  
                 Patients eligible for inclusion in this study must  
               
               
                   
                 fulfill all of the following criteria:  
               
               
                   
                 1. Able to understand and communicate with the  
               
               
                   
                 investigator, willing and capable to comply with  
               
               
                   
                 all study procedures, and provide written signed  
               
               
                   
                 and dated informed consent (personally or by a  
               
               
                   
                 witness) before any assessment is performed  
               
               
                   
                 2. Aged 18 to 50 years inclusive  
               
               
                   
                 3. New-onset plaque psoriasis with appearance of  
               
               
                   
                 the first psoriasis plaques within the last 12  
               
               
                   
                 months before randomization and naïve to any  
               
               
                   
                 systemic treatment and phototherapy (Arms A1,  
               
               
                   
                 A2 and Arm B1)  
               
               
                   
                 4. Chronic plaque psoriasis with appearance of  
               
               
                   
                 the first psoriasis symptoms 5 years or longer and  
               
               
                   
                 intolerance or inadequate response to  
               
               
                   
                 phototherapy or any systemic treatment including  
               
               
                   
                 biologicals, except for IL-17A inhibitors (Arm  
               
               
                   
                 C1 and Arm C2)  
               
               
                   
                 5. Moderate to severe plaque psoriasis defined at  
               
               
                   
                 screening and baseline by PASI ≥10, and body  
               
               
                   
                 surface area (BSA) ≥10%, and IGA mod 2011 ≥3  
               
               
                 Key exclusion criteria  
                 Patients fulfilling any of the following criteria  
               
               
                   
                 will not be eligible for inclusion in this study:  
               
               
                   
                 1. Forms of psoriasis other than plaque-type  
               
               
                   
                 (e.g., pustular, erythrodermic, guttate, light  
               
               
                   
                 sensitive, and drug induced)  
               
               
                   
                 2. Ongoing use of prohibited treatments  
               
               
                   
                 3. Previous treatment with phototherapy or any  
               
               
                   
                 systemic treatment  
               
               
                   
                 4. Pregnant or nursing (lactating) women  
               
               
                   
                 5. Women of childbearing potential, defined as  
               
               
                   
                 all women physiologically capable of becoming  
               
               
                   
                 pregnant, unless they are using effective methods  
               
               
                   
                 of contraception during the Treatment Epoch or  
               
               
                   
                 longer if required by locally-approved  
               
               
                   
                 prescribing information (e.g., 20 weeks in the EU  
               
               
                   
                 for secukinumab)  
               
               
                 Study treatment  
                 Secukinumab (AIN457) 300 mg  
               
               
                   
                 Narrow-band UVB  
               
               
                 Efficacy assessments  
                 Body surface area and psoriasis area severity  
               
               
                   
                 index  
               
               
                   
                 Investigator&#39;s global assessment mod 2011  
               
               
                   
                 Subject&#39;s assessment of pain, itching and scaling  
               
               
                   
                 Subject&#39;s global assessment of psoriatic disease  
               
               
                 Safety assessments  
                 Physical examination  
               
               
                   
                 Vital signs  
               
               
                   
                 Height and body weight  
               
               
                   
                 Laboratory evaluations (hematology, clinical  
               
               
                   
                 chemistry, high-sensitivity C-reactive protein)  
               
               
                   
                 Electrocardiogram  
               
               
                   
                 Pregnancy  
               
               
                   
                 Adverse events  
               
               
                 Other assessments  
                 Evaluation of psoriatic arthritis symptoms  
               
               
                   
                 Dermatology life quality index  
               
               
                   
                 Work productivity and activity impairment  
               
               
                   
                 questionnaire: psoriasis  
               
               
                   
                 Immunological analysis of skin biopsies  
               
               
                   
                 Human β-defensin 2  
               
               
                 Data analysis  
                 The primary efficacy variable is the proportion of  
               
               
                   
                 patients who achieve PASI 90 at Week 52. The  
               
               
                   
                 analysis for the primary objective will be based  
               
               
                   
                 on the full analysis set.  
               
               
                   
                 For the primary analysis, the following  
               
               
                   
                 hypothesis testing will be performed:  
               
               
                   
                 H 01 : p sec  = p nbUVB  versus H A1 : p sec  ≠ p nbUVB    
               
               
                   
                 The primary analysis method for PASI 90  
               
               
                   
                 response at Week 52 will use an exact logistic  
               
               
                   
                 regression model with treatment as an  
               
               
                   
                 explanatory variable and baseline PASI score as  
               
               
                   
                 covariate.  
               
               
                   
                 The key secondary variable is the proportion of  
               
               
                   
                 all randomized patients who achieve PASI 90 at  
               
               
                   
                 Week 104. In order to reduce selection bias, all  
               
               
                   
                 patients who do not achieve PASI 90 at Week 52  
               
               
                   
                 will also be included in the analysis at Week 104  
               
               
                   
                 using the PASI improvement obtained at Week  
               
               
                   
                 104 only.  
               
               
                   
                 For the key secondary analysis, the following  
               
               
                   
                 hypothesis testing will be performed:  
               
               
                   
                 H 02 : p* sec  = p* nbUVB  versus H A2 : p* sec  ≠ p* nbUVB    
               
               
                 Keywords  
                 Psoriasis, IL-17A, secukinumab, narrow-band  
               
               
                   
                 UVB, PASI  
               
               
                 Brief title  
                 Study of the efficacy of early intervention with  
               
               
                   
                 secukinumab 300 mg s.c. compared to narrow- 
               
               
                   
                 band UVB in patients with new-onset moderate  
               
               
                   
                 to severe plaque psoriasis  
               
               
                 Investigation type  
                 Drug  
               
               
                 Study type  
                 Interventional  
               
               
                 Purpose and rationale  
                 The purpose of this study is to determine whether  
               
               
                   
                 early intervention with subcutaneous (s.c.)  
               
               
                   
                 secukinumab 300 mg in patients with new-onset  
               
               
                   
                 moderate to severe plaque psoriasis may lead  
               
               
                   
                 to prolonged symptom-free periods by preventing  
               
               
                   
                 reactivation of old lesions or ultimately totally  
               
               
                   
                 hindering the occurrence of new lesions, i.e.,  
               
               
                   
                 changing the natural course of the disease (Main  
               
               
                   
                 Study).  
               
               
                 Primary objective  
                 To demonstrate that early treatment with  
               
               
                   
                 secukinumab 300 mg s.c. (Arm A1) is superior to  
               
               
                   
                 standard of care treatment with nb-UVB (Arm  
               
               
                   
                 B1) in patients with new-onset moderate to  
               
               
                   
                 severe plaque psoriasis with respect to patients  
               
               
                   
                 achieving ≥90% improvement (reduction) in  
               
               
                   
                 psoriasis area and severity index (PASI 90) 
               
               
                   
                 response at Week 52.  
               
               
                 Secondary objectives  
                 Key secondary objective  
               
               
                   
                 To evaluate the superiority of early treatment  
               
               
                   
                 with secukinumab (Arm A1) versus nb-UVB  
               
               
                   
                 (Arm B1) based on the proportion of all  
               
               
                   
                 randomized patients who achieve at least PASI  
               
               
                   
                 90 at Week 104.  
               
               
                   
                 Additional secondary objective  
               
               
                   
                 To evaluate the effects of early treatment with  
               
               
                   
                 secukinumab (Arm A1) compared with nb-UVB  
               
               
                   
                 (Arm B1) based on the proportion of all  
               
               
                   
                 randomized patients who achieve at least  
               
               
                   
                 investigator&#39;s global assessment (IGA mod  
               
               
                   
                 2011) of 0 or 1 at Week 52 and at Week 104.  
               
               
                 Study design  
                 The design consists of the Main Study involving  
               
               
                   
                 all patients in Arms A1 (A1a and A1b) and B1  
               
               
                   
                 (B1a and B1b) and a Mechanistic Sub-study,  
               
               
                   
                 which comprises 5 treatment arms (A1b, A2,  
               
               
                   
                 B1b, C1, and C2).  
               
               
                   
                 The Main Study will be multicenter, randomized,  
               
               
                   
                 2-treatment-arm (secukinumab and nb-UVB),  
               
               
                   
                 parallel-group and open-label.  
               
               
                 Population  
                 The overall study population (Main Study and  
               
               
                   
                 Mechanistic Sub-study) will consist of a total of  
               
               
                   
                 196 male and female patients aged between 18  
               
               
                   
                 and 50 years inclusive.  
               
               
                   
                 Main Study  
               
               
                   
                 The Main Study will be conducted in patients  
               
               
                   
                 with new-onset moderate to severe plaque  
               
               
                   
                 psoriasis not previously treated with any  
               
               
                   
                 systemic treatment or phototherapy.  
               
               
                   
                 A total of 160 patients will be randomized to  
               
               
                   
                 Arm A1 or Arm B1 in approximately 75 sites  
               
               
                   
                 worldwide. Since a maximum screening failure  
               
               
                   
                 rate of 20% is expected, approximately 245  
               
               
                   
                 patients will be screened.  
               
               
                   
                 Mechanistic Sub-study  
               
               
                   
                 Any patient who consents can participate in the  
               
               
                   
                 Mechanistic Sub-study. Patients with new-onset  
               
               
                   
                 plaque psoriasis will be randomized to Arm A1b,  
               
               
                   
                 Arm A2, or Arm B1b, those with chronic plaque  
               
               
                   
                 psoriasis will be randomized to Arm C1 and Arm  
               
               
                   
                 C2 (12 patients each). For Arm A1b or Arm B1b,  
               
               
                   
                 the first 12 patients will be included on a first  
               
               
                   
                 come first serve basis.  
               
               
                 Key inclusion criteria  
                 Patients eligible for inclusion in this study must  
               
               
                   
                 fulfill all of the following criteria:  
               
               
                   
                 6. Able to understand and communicate with the  
               
               
                   
                 investigator, willing and capable to comply with  
               
               
                   
                 all study procedures, and provide written signed  
               
               
                   
                 and dated informed consent (personally or by a  
               
               
                   
                 witness) before any assessment is performed  
               
               
                   
                 7. Aged 18 to 50 years inclusive  
               
               
                   
                 8. New-onset plaque psoriasis with appearance of  
               
               
                   
                 the first psoriasis plaques within the last 12  
               
               
                   
                 months before randomization and naïve to  
               
               
                   
                 any systemic treatment and phototherapy (Arms  
               
               
                   
                 A1, A2 and Arm B1)  
               
               
                   
                 9. Chronic plaque psoriasis with appearance of  
               
               
                   
                 the first psoriasis symptoms 5 years or longer and  
               
               
                   
                 intolerance or inadequate response to  
               
               
                   
                 phototherapy or any systemic treatment including  
               
               
                   
                 biologicals, except for IL-17A inhibitors (Arm  
               
               
                   
                 C1 and Arm C2)  
               
               
                   
                 10. Moderate to severe plaque psoriasis defined  
               
               
                   
                 at screening and baseline by PASI ≥10, and body  
               
               
                   
                 surface area (BSA) ≥10%, and IGA mod 2011 ≥3  
               
               
                 Key exclusion criteria  
                 Patients fulfilling any of the following criteria  
               
               
                   
                 will not be eligible for inclusion in this study:  
               
               
                   
                 6. Forms of psoriasis other than plaque-type  
               
               
                   
                 (e.g., pustular, erythrodermic, guttate, light  
               
               
                   
                 sensitive, and drug induced)  
               
               
                   
                 7. Ongoing use of prohibited treatments  
               
               
                   
                 8. Previous treatment with phototherapy or any  
               
               
                   
                 systemic treatment  
               
               
                   
                 9. Pregnant or nursing (lactating) women  
               
               
                   
                 10. Women of childbearing potential, defined as  
               
               
                   
                 all women physiologically capable of becoming  
               
               
                   
                 pregnant, unless they are using effective methods  
               
               
                   
                 of contraception during the Treatment Epoch or  
               
               
                   
                 longer if required by locally-approved  
               
               
                   
                 prescribing information (e.g., 20 weeks in the EU  
               
               
                   
                 for secukinumab)  
               
               
                 Study treatment  
                 Secukinumab (AIN457) 300 mg  
               
               
                   
                 Narrow-band UVB  
               
               
                 Efficacy assessments  
                 Body surface area and psoriasis area severity  
               
               
                   
                 index  
               
               
                   
                 Investigator&#39;s global assessment mod 2011  
               
               
                   
                 Subject&#39;s assessment of pain, itching and scaling  
               
               
                   
                 Subject&#39;s global assessment of psoriatic disease  
               
               
                 Safety assessments  
                 Physical examination  
               
               
                   
                 Vital signs  
               
               
                   
                 Height and body weight  
               
               
                   
                 Laboratory evaluations (hematology, clinical  
               
               
                   
                 chemistry, high-sensitivity C-reactive protein)  
               
               
                   
                 Electrocardiogram  
               
               
                   
                 Pregnancy  
               
               
                   
                 Adverse events  
               
               
                 Other assessments  
                 Evaluation of psoriatic arthritis symptoms  
               
               
                   
                 Dermatology life quality index  
               
               
                   
                 Work productivity and activity impairment  
               
               
                   
                 questionnaire: psoriasis  
               
               
                   
                 Immunological analysis of skin biopsies  
               
               
                   
                 Human β-defensin 2  
               
               
                 Data analysis  
                 The primary efficacy variable is the proportion of  
               
               
                   
                 patients who achieve PASI 90 at Week 52. The  
               
               
                   
                 analysis for the primary objective will be based  
               
               
                   
                 on the full analysis set.  
               
               
                   
                 For the primary analysis, the following  
               
               
                   
                 hypothesis testing will be performed:  
               
               
                   
                 H01: psec = pnbUVB versus HA1:  
               
               
                   
                 psec ≠ pnbUVB  
               
               
                   
                 The primary analysis method for PASI 90  
               
               
                   
                 response at Week 52 will use an exact logistic  
               
               
                   
                 regression model with treatment as an  
               
               
                   
                 explanatory variable and baseline PASI score as  
               
               
                   
                 covariate.  
               
               
                   
                 The key secondary variable is the proportion of  
               
               
                   
                 all randomized patients who achieve PASI 90 at  
               
               
                   
                 Week 104. In order to reduce selection bias, all  
               
               
                   
                 patients who do not achieve PASI 90 at Week 52  
               
               
                   
                 will also be included in the analysis at Week 104  
               
               
                   
                 using the PASI improvement obtained at Week  
               
               
                   
                 104 only.  
               
               
                   
                 For the key secondary analysis, the following  
               
               
                   
                 hypothesis testing will be performed:  
               
               
                   
                 H02: p*sec = p*nbUVB versus HA2:  
               
               
                   
                 p*sec ≠ p*nbUVB  
               
               
                 Keywords  
                 Psoriasis, IL-17A, secukinumab, narrow-band  
               
               
                   
                 UVB, PASI